ليست عنوان مقالات لاتين 2, 2′-Dihydroxyazobenzene-based fluorescent system for the colorimetric ‘turn-on’ sensing of cyanide 2010 IAGR Annual Convention and 7th International Symposium on Gondwana to Asia

<< مقالات لاتين >>

<< بر اساس عنوان >>

1

2, 2′-Dihydroxyazobenzene-based fluorescent system for the colorimetric ‘turn-on’ sensing of cyanide

2

2, 3-(2-alkylthio)-6,7-bis(2-alkylthio)TTF: a new and green synthetic anticorrosive inhibitors for mild steel in 1.0 HCl

3

2, 3-Dihydrazone cellulose: Prospective material for tissue engineering scaffolds

4

2, 4-D Dichlorophenoxyacetic Acid Poisoning; Case Report and Literature Review

5

2,000 sets of Airbus wings

6

2,1,3-Benzothiadiazole-containing donor–acceptor–acceptor dyes for dye-sensitized solar cells

7

2,1,3-Benzoxadiazole-based selective chromogenic chemosensor for rapid naked-eye detection of Hg2+ and Cu2+

8

2,15-Dihydroxy-hexahelicene (HELIXOL): synthesis and use as an enantioselective fluorescent sensor

9

2,2,2-Trifluoroethyl 6-thio-β-d-glucopyranoside as a selective tag for cysteines in proteins Original Research Article

10

2,2,2-Trifluoroethyl methacrylate-graft-natural rubber: Synthesis and application as compatibilizer in natural rubber/fluoroelastomer blends

11

2,2,3,3,11,11,12,12-Octamethyl-1,4,7,10,13-pentaoxacyclohexadecane: improved synthesis and crystal structure with NaSCN

12

2,2,3,3,6,6-Hexachlorobiphenyl Hydroxylation by Active Site Mutants of Cytochrome P450 2B1 and 2B11

13

2,2,4,4-Tetrathio substituted 1,3-dithietanes

14

2,2,6,6-Tetramethylcyclohexanethione S-methylide, a highly hindered thiocarbonyl ylide: two-step cycloadditions

15

2,2,6,6-Tetramethylpiperidine-1-yloxyl bound to the imidazolium ion by an acetamido group for investigation of ionic liquids

16

2,2ʹ:6ʹ,2ʹʹ-Terpyridine metal complexes as building blocks for extended functional metallo-supramolecular assemblies and polymers

17

2,2′-(Disulfanediyl)dibenzoic acid N,N-dimethylformamide monosolvate: crystal structure, Hirshfeld surface analysis and computational study

18

2,2′,3,3′,4,4′-Hexachlorobiphenyl subchronic toxicity in rats

19

2,2′,3,4-Tetrahydroxy-3′-sulpho-5′-nitroazobenzene for spectrophotometric determination of aluminium in pharmaceutical suspensions and granite Original Research Article

20

2,2′:6′,2″-Terpyridine and bis(2,2′:6′,2″-terpyridine)ruthenium(II) complex on the dendritic periphery

21

2,2′:6′,2″-Terpyridine complexes of molybdenum(II) and tungsten(II). X-ray crystal structures of [MoI(CO)(terpy)(η2-PhC2Ph)]I and [WI(terpy)(η2-PhC2Ph)2]I·CDCl3

22

2,2′:6′,2″-Terpyridine[hydroxypropyl-β-cyclodextrin] 1:3 complex used as chelating agent for the determination of iron with a sensitive, selective and fast liquid chromatographic method Original Research Article

23

2,2′-Azobis (4-Methoxy-2,4-Dimethylvaleronitrile), a New Lipid-Soluble Azo Initiator: Application to Oxidations of Lipids and Low-Density Lipoprotein in Solution and in Aqueous Dispersions

24

2,2′-Biphenyldiol-bridged bis(free base porphyrin): synthesis and chiroptical probing of asymmetric amino alcohols

25

2,2′-Bipyridine and related N-chelants as very effective promoters for Cu catalysts in the decarboxylation

26

2,2′-Bipyridine, 2-(2-oxazolyl)pyridine and 2,2′-bisoxazole derived nickel(0) complexes as selective catalysts for cross-coupling of aryl chlorides by intramolecularly stabilized dialkylaluminum reagents

27

2,2′-Bipyridine,1,10-phenanthroline and 2,2′:6′,2″-terpyridine in gallium(III) chemistry: Complexes containing the core

28

2,2′-Bipyridinebutyldithiocarbamatoplatinum(II) and palladium(II) complexes: Synthesis, characterization, cytotoxicity, and rich DNA-binding studies Original Research Article

29

2,2′-Bipyrimidine transition metal complexes: Synthesis, reaction chemistry and solid state structures

30

2,2′-Bis((di-tert-butylphosphino)methyl)-1,1′-biphenyl (ditbi): a bulky analogue of bisbi. The crystal structure of [Rh2Cl2(1,5-cod)2(μ-ditbi)]

31

2,2′-Bis(diarylstibano)-1,1′-binaphthyls (BINASbs); a useful chiral ligand for palladium-catalyzed asymmetric allylic alkylation, and the structure of a BINASbPdCl2 complex

32

2,2′-Diamino-6,6′-dimethylbiphenyl as an efficient ligand in the palladium-catalyzed Suzuki–Miyaura and Mizoroki–Heck reactions

33

2,2′-Diaminoazo-benzene, a potential scaffold for the synthesis of bis-ureas and thioureas: Solution phase anion sensing and binding studies

34

2,2′-Dilithiobiphenyl by direct lithiation of biphenylene

35

2,2′-dithiobisbenzamides derived from α-, β- and γ-amino acids possessing anti-HIV activities: synthesis and structure–activity relationship Original Research Article

36

2,2′-Oxydiacetato-bridged complexes containing Sm(III) and bivalent cations. Synthesis, structure, magnetic properties and chemical speciation

37

2,2′-Pyridoin derivatives protect HL-60 cells against oxidative stress

38

2,2-Bipyridine: An Efficient Ligand in the Cobalt-Catalyzed Synthesis of Organozinc Reagents from Aryl Chlorides and Sulfonates

39

2,2-Bipyrimidine- and 2,3-bis(2-pyridyl)pyrazine-containing manganese(II) compounds: structural and magnetic properties

40

2,2-Bis(3-allyl-4-hydroxyphenyl)hexafluoropropane and fluorosiloxane as coating materials for nerve agent sensors

41

2,2-Dichlorination of Aldehydes with the 2,6-Lutidine·HCl/Cl2/CH2Cl2 System: an Environmentally Benign Process Suitable for Scale Up

42

2,2-Dichlorobiphenyl Decreases Amplitude and Synchronization of Uterine Contractions Through MAPK1-Mediated Phosphorylation of GJA1 (Connexin43) and Inhibition of Myometrial Gap Junctions

43

2,2-dicyanovinyl as a nonaromatic aryl bioisostere: synthesis, binding experiments and SAR studies of highly selective dopamine D4 receptor ligands

44

2,2-Dihydroperfluoropentane (HFC 4310 mf) synthesis from HFP dimer

45

2,2-Dihydroxy-methylcyclosiloxanes and other 2,2-difunctional methylcyclosiloxanes

46

2,2-Dimethoxy-propane as electrolyte additive for lithium-ion batteries

47

2,2-Dimethyl cyclopentanones by acid catalyzed ring expansion of isopropenylcyclobutanols. A short synthesis of ((plus-minus))-(alpha)-cuparenone and ((plus-minus))-herbertene

48

2,2-Dimethyl-2-(o-nitrophenyl)acetyl (DMNA) as an assisted cleavage protecting group for amines

49

2,2-Dimethyl-2H-anthra[2,3-b]pyran-6,11-diones: a new class of cytotoxic compounds Original Research Article

50

2,2-Dimethyl-4,5-diaryl-3(2H)furanone derivatives as selective cyclo-oxygenase-2 inhibitors

51

2,2-Disubstituted analogues of the natural hormone 1α,25-dihydroxyvitamin D3: chemistry and biology Original Research Article

52

2,2-Hydroxyphenylbenzoxazole as a selective chelating agent for complexation with Tin and Zinc: a voltammetry study

53

2,3,4,5-Tetrahydro- and 2,3,4,5,11,11a-hexahydro-1H-[1,4]diazepino[1,7-a]indoles: new templates for 5-HT2C agonists

54

2,3,5,6,7,8-Hexasilabicyclo[2.2.2]octane-1-carboxylic acids and esters: preparation and structure

55

2,3,5,6-Tetra(pyrazin-2-yl)pyrazine: a novel bis-bidentate, bis-tridentate chelator

56

2,3,5-Substituted tetrahydrofurans as cancer chemopreventives. Part 1: Synthesis and anti-cancer activities of 5-hydroxymethyl-2,3-diaryl-tetrahydro-furan-3-ols Original Research Article

57

2,3,5-Trimethylphenol oxidation over Co-based solid catalysts Original Research Article

58

2,3,5-Triphenyltetrazolium chloride (TTC) as electron acceptor of culturable soil bacteria, fungi and actinomycetes

59

2,3,6,7-Naphthalenetetracarboxylic dianhydride revisited

60

2,3,6-/3,4,5-Trimethyl substituted diaryl carotenoid derivatives (Chlorobiaceae) in petroleums of the Belarussian Pripyat River Basin

61

2,3,6-Trideoxy sugar nucleotides: synthesis and stability

62

2,3,7,8-Substituted PCDDs and PCDFs in sea lion (Otaria flavescens) skin biopsies from two South-western Atlantic populations

63

2,3,7,8-TCDD equivalence and mutagenic activity associated with PM10 from three urban locations in New Zealand

64

2,3,7,8-Tetrachlorodibenzo-p-dioxin induces a proteomic pattern that defines cleft palate formation in mice

65

2,3,7,8-Tetrachlorodibenzo-p-dioxin induces CYP1B1 expression in human luteinized granulosa cells

66

2,3,7-Trisubstituted pyrazolo[1,5-d][1,2,4]triazines: Functionally selective GABAA α3-subtype agonists

67

2,3′-disubstituted-2-(2′-carboxycyclopropyl)glycines as potent and selective antagonists of metabotropic glutamate receptors

68

2,392 emergency department intubations: First report of the ongoing National Emergency Airway Registry study (NEAR 97)

69

2,3-Anhydrosugars in glycoside bond synthesis. Application to the preparation of C-2 functionalized α-d-arabinofuranosides

70

2,3-Anhydrosugars in glycoside bond synthesis: application to furanosyl azides and C-glycosides

71

2,3-Benzodiazepin-1,4-diones as peptidomimetic inhibitors of γ-secretase

72

2,3-Butanediol fermentation promotes growth of Serratia plymuthica at low pH but not survival of extreme acid challenge

73

2,3-Butanedione monoxime cardioplegia: advantages over hyperkalemia in blood-perfused isolated hearts

74

2,3-Dehydro-4α-hydroxylongilactone, a novel quassinoid and two known phenyl propanoids from Eurycoma longifolia Jack

75

2,3-Diamino acid modifying 3S-tetrahydroisoquinoline-3-carboxylic acids: Leading to a class of novel agents with highly unfolded conformation, selective in vitro anti-platelet aggregation and potent in vivo anti-thrombotic activity Original Research Artic

76

2,3-Diaminopyridine as a platform for designing structurally unique nonpeptide bradykinin B1 receptor antagonists

77

2,3-Diaryl-5-anilino[1,2,4]thiadiazoles as melanocortin MC4 receptor agonists and their effects on feeding behavior in rats Original Research Article

78

2,3-Diarylbenzopyran derivatives as a novel class of selective cyclooxygenase-2 inhibitors

79

2,3-Diarylpyran-4-ones: a new series of selective cyclooxygenase-2 inhibitors

80

2,3-Diarylthiophenes as selective EP1 receptor antagonists

81

2,3-Dichloro-5,6-dicyano-p-benzoquinone (DDQ) as a Highly Efficient and Mild Catalyst for Diethyl Acetalization of Carbonyl Compounds

82

2,3-Dihydro-1,3-dioxo-1H-isoindole-5-carboxylic acid derivatives: a novel class of small molecule heparanase inhibitors

83

2,3-Dihydro-1H-1,3-diazepin-2-ones: synthesis and novel rearrangements into pyrrole derivatives

84

2,3-Dihydro-5-hydroxy-2,2-dipentyl-4,6-di-tert-butylbenzofuran: Design and Evaluation as a Novel Radical-Scavenging Antioxidant against Lipid Peroxidation

85

2,3-Dihydro-6,7-dichloro-pyrido[2,3-b]pyrazine-8-oxide as selective glycine antagonist with in vivo activity Original Research Article

86

2,3-Dihydro-dithiin and -dithiepine-1,1,4,4-tetroxides: small molecule non-peptide antagonists of the human galanin hGAL-1 receptor Original Research Article

87

2,3-Dihydrofarnesyl and citronellyl esters in the paracloacal gland secretions of the brown caiman (Caiman crocodilus fuscus) from Costa Rica

88

2,3-Dihydroimidazo[1,2-b]ferroceno[d]pyridazines and a 3,4-dihydro-2H-pyrimido[1,2-b]ferroceno[d]pyridazine: Synthesis, structure and in vitro antiproliferation activity on selected human cancer cell lines

89

2,3-Dihydroisoindolones by cyclisation and rearomatisation of lithiated benzamides

90

2,3-Dihydroxypropyl methacrylate and 2-hydroxyethyl methacrylate hydrogels: gel structure and transport properties

91

2,3-Dimercaptopropanol, 2,3-dimercaptopropane-1-sulfonic acid, and meso-2,3-dimercaptosuccinic acid inhibit δ-aminolevulinate dehydratase from human erythrocytes in vitro

92

2,3-Dimethoxy-5-methyl-1,4-benzoquinones and 2-methyl-1,4-naphthoquinones: glycation inhibitors with lipid peroxidation activity

93

2,3-Dimethoxybenzo[i]phenanthridines: topoisomerase I-targeting anticancer agents Original Research Article

94

2,3-Dimethyl-2,3-diphenylbutane mediated grafting of vinyltriethoxysilane to polyethylene: a novel radical initiation system

95

2,3-Di-O-methoxymethyl-6-O-tert-butyldimethylsilyl-β-cyclodextrin, a useful stationary phase for gas chromatographic separation of enantiomers

96

2,3-Di-O-methoxymethyl-6-O-tert-butyldimethylsilyl-γ-cyclodextrin: a new class of cyclodextrin derivatives for gas chromatographic separation of enantiomers

97

2,3-Diphenylpropionic acids as potent VLA-4 antagonists

98

2,3-Diphenylquinoxaline-4′,4″-dioxytriethylene glycol as a sensing and selective material for construction of strontium-PVC membrane sensor

99

2,3-Disubstituted 6-azabicyclo[3.2.1]octanes as novel dopamine transporter inhibitors Original Research Article

100

2,3-Disubstituted pyrrolo[2,3-b]quinoxalines via aminopalladation–reductive elimination

101

2,3-Disubstituted quinuclidines as a novel class of dopamine transporter inhibitors Original Research Article

102

2,3-DPG-Hb complex: a hypothesis for an asymmetric binding Original Research Article

103

2,3-Epithiopropyl methacrylate as functionalized monomer in a dental adhesive

104

2,3-Ethylene- and 2,3-trimethylene-bridged analogues of the group III metabotropic glutamate receptor ligand 2-amino-4-phosphonobutanoic acid

105

2,3-Quinoxalinedione as a novel corrosion inhibitor for mild steel in 1 M HCl

106

2,3-Substituted 2-azanorbornanes as polar β-turn mimetics

107

2,3-Unsaturated enoses. A Pummerer rearrangement route to sugar vinyl sulfides and synthesis of 3-deoxy-3-alkyl/arylsulfinyl pyranosides

108

2,4- في استحداث الكالس وتحفيز الاجنه الخضريه من زراعه البراعم D و NAA تاثير الاوكسينان بتقنيه زراعه الانسجه Ananas comosus (L.) Merr. cv. DelMonte الابطيه لنبات الاناناس

109

2,4(5)-Diarylimidazoles: Synthesis and biological evaluation of a new class of sodium channel blockers against hNav1.2

110

2,4,4,5,7,7,8,8,9,9,9-Undecafluoro-2,5-bis(trifluoromethyl)-3,6-dioxanonyl methacrylate

111

2,4,5- triarylimidazole inhibitors of IL-1 biosynthesis

112

2,4,5-Trimethoxypropiophenone from Piper marginatum

113

2,4,5-Trisubstituted imidazoles: novel nontoxic modulators of P-glycoprotein mediated multidrug resistance. Part 1[]

114

2,4,5-Trisubstituted imidazoles: novel nontoxic modulators of P-glycoprotein mediated multidrug resistance. Part 2[]

115

2,4,5-Trisubstituted Thiazole Building Blocks by a Novel Multi-Component Reaction

116

2,4,6,8-Tetraiodoglycoluril in sulfuric acid as a new powerful reagent for iodination of deactivated arenes

117

2,4,6-tri(3,5-Dimethylpyrazoyl)-1,3,5-triazine modified carbon paste electrode for trace Cobalt(II) determination by differential pulse anodic stripping voltammetry

118

2,4,6-Trichloro-1,3,5-triazine catalyzed synthesis of thiiranes from oxiranes under solvent-free and mild conditions

119

2,4,6-Trihydroxyacetophenone on zeolite surface: Correlation between electronic relaxation and fragmentation on mass spectra

120

2,4,6-Trimethylpyridinium perchlorate: Polar properties and correlations with molecular structure of organic–inorganic hybrid crystal

121

2,4,6-Trinitrotoluene transformation by a tropical marine yeast, Yarrowia lipolytica NCIM 3589

122

2,4,6-Trinitrotoluene Transformation Using Spinacia Oleracea: Saturation Kinetics of the Nitrate Reductase Enzyme

123

2,4,6-Triphenylphenyltellurium(IV) triiodide – supramolecular self-assembling in organotellurium triiodides

124

2,4,6-Triphenylpyrylium ion encapsulated within Y zeolite as photocatalyst for the degradation of methyl parathion

125

2,4,6-Triphenylthiapyrylium cation as homogeneous solar photocatalyst

126

2,4,6-Tris(4-iodophenoxy)-1,3,5-triazine as a new recyclable “iodoarene” for in situ generation of hypervalent iodine(III) reagent for α-tosyloxylation of enolizable ketones

127

2,4,6-Trisubstituted pyridines: Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure–activity relationship Original Research Article

128

2,4,6-Trisubstituted pyrimidine derivatives as pregnancy interceptive agents Original Research Article

129

2,4,6-Tri-tert-butyl-1,3,5-triphosphabenzene as an (eta)6-Ligand in Transition Metal Complexes

130

2,4-Bis(fluorocarbon)-substituted phenols for high yield Newman–Kwart rearrangement reactions

131

2,4-Bis(methylsulfanyl)pyrimidine o-quinodimethane: a versatile building block for functionalized fused pyrimidines

132

2,4-Bis(octadecanoylamino)benzenesulfonic acid sodium salt as a novel scavenger receptor inhibitor with low molecular weight

133

2,4-Bridged 1,5-bis(fluoroalkyl)-1,3,5-triketones: synthesis and properties

134

2,4-D based herbicidal ionic liquids

135

2,4-D Exposure and risk assessment: Comparison of external dose and biomonitoring based approaches

136

2,4-Decadienal downregulates TNF-α gene expression in THP-1 human macrophages

137

2,4-Diamino-5-methyl-6-substituted arylthio-furo[2,3-d]pyrimidines as novel classical and nonclassical antifolates as potential dual thymidylate synthase and dihydrofolate reductase inhibitors Original Research Article

138

2,4-Diamino-9H-pyrimido[4,5-b]indol-5-ols: Synthesis, in vitro cytotoxic activity, and QSAR investigations Original Research Article

139

2,4-Diaminopyrimidines as histamine H4 receptor ligands—Scaffold optimization and pharmacological characterization Original Research Article

140

2,4-Diaminopyrimidines as inhibitors of Leishmanial and Trypanosomal dihydrofolate reductase Original Research Article

141

2,4-Diaryltetrahydropyran Formation by the Prins Cyclization and Its Application towards the Synthesis of Epicalyxin F and Calyxin I

142

2,4-Diazido-5-iodo-pyrimidine crystal under high pressure: A comparison of DFT and DFT-D studies

143

2,4-Dicarboxy-pyrroles as selective non-Competitive mGluR1 antagonists: further characterization of 3,5-Dimethyl pyrrole-2,4-dicarboxylic acid 2-propyl ester 4-(1,2,2-Trimethyl-propyl) ester and structure–Activity relationships

144

2,4-Dichlorophenol (DCP) containing wastewater treatment using a hybrid-loop bioreactor

145

2,4-Dichlorophenoxy acetic acid, abscisic acid, andhydrogen peroxide induced resistance-related components against potato early blight (Alternaria solani, Sorauer)

146

2,4-Dichlorophenoxyacetic acid (2,4-D) biodegradation in river sediments of Northeast-Scotland and its effect on the microbial communities (PLFA and DGGE)

147

2,4-Dichlorophenoxyacetic acid (2,4-D) sorption and degradation dynamics in three agricultural soils

148

2,4-dichlorophenoxyacetic acid adsorption from contaminated water through activated carbon reclaimed with zero-valent iron and titanium dioxide

149

2,4-Dichlorophenoxyacetic acid degradation by catalyzed ozonation: TiO2/UVA/O3 and Fe(II)/UVA/O3 systems

150

2,4-dichlorophenoxyacetic acid-induced leaf senescence in mung bean (Vigna radiata L. Wilczek) and senescence inhibition by co-treatment with silver nanoparticles

151

2,4-Dienoyl-CoA Reductase from Escherichia coli Is a Novel Iron–Sulfur Flavoprotein That Functions in Fatty Acid β-Oxidation

152

2,4-Dimethoxyphenylsemicarbazones with anticonvulsant activity against three animal models of seizures: Synthesis and pharmacological evaluation Original Research Article

153

2,4-Dimethylphenol imprinted polymers as a solid-phase extraction sorbent for class-selective extraction of phenolic compounds from environmental water

154

2,4-Dinitro-3,5,6-trideuterophenylhydrazones for the quantitation of aldehydes and ketones in air samples by liquid chromatography–mass spectrometry

155

2,4-Dinitrophenol adsorption by date seeds: Effect of physico-chemical environment and regeneration study Original Research Article

156

2,4-Dinitrophenol and Carbonylcyanide p-Trifluoromethoxyphenylhydrazone Activate the Glutathione S-Conjugate Transport ATPase of Human Erythrocyte Membranes

157

2,4-Dinitrophenol as an activating reagent in a facile preparation of cyclic phosphate triesters

158

2,4-Dinitrophenol reduces the reactivity of Lys553 in the lower 50-kDa region of myosin subfragment 1

159

2,4-Dinitrophenol: a novel activating reagent in nucleotide synthesis via the phosphoramidite route. Design of new effective phosphitylating reagents

160

2,4-Disubstituted oxazoles and thiazoles as latent pharmacophores for diacylhydrazine of SC-51089, a potent PGE2 antagonist Original Research Article

161

2,4-Disubstituted piperidines as selective CC chemokine receptor 3 (CCR3) antagonists: Synthesis and selectivity

162

2,4-Disubstituted pyrimidines: A novel class of KDR kinase inhibitors

163

2,4-Disubstituted pyrroles: synthesis, traceless linking and pharmacological investigations leading to the dopamine D4 receptor partial agonist FAUC 356

164

2,4-Disubstituted-5-acetoxythiazoles: useful intermediates for the synthesis of thiazolones and 2,4,5-trisubstituted thiazoles

165

2,4-thiazolidinediones as potent and selective human β3 agonists

166

2,5,7-Trisubstituted benzo[b]furans through a copper- and/or palladium-catalyzed assembly and functionalization process

167

2,5-Anhydro sugar diacid and 2,5-anhydro sugar diamine based C2 symmetric peptidomimetics as potential HIV-1 protease inhibitors

168

2,5-Bis(1,3-dithiol-2-ylidene)-1,3,4,6-tetrathiapentalene (TTP) derivatives having four long alkylthio chains

169

2,5-Bis-(2-hydroxybenzoylamino)pentanoic acid, a salicylic acid-metabolite isolated from chicken: characterization and independent synthesis

170

2,5-Bis-(butyltelluro) thiophene as a convenient precursor for the synthesis of 2,5-bis-(acetylenic) thiophenes

171

2,5-Bis(diphenylmethylene)-3-cyclopentenone: a solvent-dependent cobalt cluster mediated propargyl radical coupling process

172

2,5-Bis(pyridyl)pyrazine PtM, Pt2M and Ti2M2 transition metal complexes (M = Cu, Ag)

173

2,5-Bis-(sulfonyl)pyrazines as unprecedented building blocks and their SNAr reactions

174

2,5-Bis{N-(2,6-diisopropylphenyl)iminomethyl}pyrrolyl borohydride complexes of the divalent lanthanides – Synthesis, structures and ring-opening polymerization of ε-caprolactone

175

2,5-Deoxyfructosazine, a d-glucosamine derivative, inhibits T-cell interleukin-2 production better than d-glucosamine Original Research Article

176

2,5-di(thiophen-2-yl)thiazolo[5,4-d]thiazole-based donor–acceptor type copolymers for photovoltaic cells

177

2,5-Diamidofuran anion receptors

178

2,5-Diaminopyrimidines and 3,5-disubstituted azapurines as inhibitors of glycogen synthase kinase-3 (GSK-3)

179

2,5-Diarylisothiazolone: novel inhibitors of cytokine-induced cartilage destruction Original Research Article

180

2,5-Dichloro-1-(ROSO2)benzene [R = C6H5, C6F5, and CH2(CF2)4H]: Synthesis, molecular structure, and solubility in supercritical CO2

181

2,5-Dideoxy-2,5-imino-d-altritol as a new class of pharmacological chaperone for Fabry disease Original Research Article

182

2,5-Difluoro-1,4-dimethoxybenzene for overcharge protection of secondary lithium batteries

183

2,5-Dihydropyrazolo[4,3-c]pyridin-3-ones: functionally selective benzodiazepine binding site ligands on the GABAA receptor

184

2,5-dihydroxybenzo-1,3,2-dithiazolylium and 2,7-dicarbonylnaphtha-1,3,2-dithiazolylium salts and their corresponding radicals Evolution of the pseudo-1,3-dipolar cycloaddition chemistry of SNSMF6(M = As, Sb) leading to

185

2,5-Diketopiperazines as potent and selective oxytocin antagonists 1: identification, stereochemistry and initial SAR

186

2,5-Dimethoxy-2,5-dihydrofuran and vinyl ethers in the synthesis of functionalised 2-alkylfurans

187

2,5-Dimethoxy-2,5-dihydrofuran chemistry: a new approach to 2(5H)-furanone derivatives

188

2,5-Dimethyl-4-hydroxy-2H-furan-3-one and its derivatives: analysis, synthesis and biosynthesis—a review

189

2,5-Dimethylbufotenine and 2,5-dimethylbufotenidine: novel derivatives of natural tryptamines found in Bufo alvarius toads

190

2,5-Disubstituted 3,4-dihydro-2H-benzo[b][1,4]thiazepines as potent and selective V2 arginine vasopressin receptor antagonists

191

2,5-Disubstituted furans from 1,4-alkynediols

192

2,5-Disubstituted pyridines: The discovery of a novel series of 5-HT2A ligands

193

2,5-Disubstituted pyrrolidine carboxylates as potent, orally active sphingosine-1-phosphate (S1P) receptor agonists

194

2,5-Di-tert-butyl-1,4-hydroquinone enhances cell transformation accompanied by an increase in intracellular free calcium ion concentration

195

2,5-Hexanedione altered the degradation of low-molecular-weight neurofilament in rat nerve tissues

196

2,5-Pyridinedicarboxylic acid derivatives as non-Nucleosidic Reverse transcriptase inhibitors of Hepatitis B Virus

197

2,6,10,15,19-Pentamethylicosenes in Methanolobus bombayensis, a marine methanogenic archaeon, and in Methanosarcina mazei

198

2,6,10-Tris(bithiophenyl)triphenylene: Synthesis and high-spin alignment in its p-doped radical derivative

199

2,6,8,9-Tetrasubstituted Purines as New CDK1 Inhibitors

200

2,6,9-Trioxabicyclo[3.3.1]nona-3,7-dien-4-oyl and tetraoxaadamantan-9-oyl functionalized aromatic di- and triamines: synthesis, stereochemistry and complexation

201

2,6,9-trisubstituted purines : Optimization towards highly potent and selective CDK1 inhibitors

202

2,6-Anhydroaldonic acids; Methyl 2,6-anhydroaldonates; 2,6-Anhydroaldonamides; Anhydroalditols; Anhydrodeoxynitroalditols

203

2,6-Bis(2-benzimidazolyl)pyridine as a chemosensor for fluoride ions

204

2,6-Bis(2-benzimidazolyl)pyridine receptor for urea recognition

205

2,6-Bis(3,4,5-trihydroxybenzylydene) derivatives of cyclohexanone: novel potent HIV-1 integrase inhibitors that prevent HIV-1 multiplication in cell-based assays Original Research Article

206

2,6-Bis(5,6-dipropyl-1,2,4-triazin-3-yl)-pyridine: Structures of An(III) and Ln(III) 1:3 complexes and selectivity

207

2,6-Bis(benzoxazoyl)pyridine (bzpybox) as a new dialkylammonium cation receptor

208

2,6-Bis(diphenylphosphino)pyridine: a simple ligand showing high performance in palladium-catalyzed CN coupling reactions

209

2,6-Bis(porphyrin)-substituted pyrazine: a new class of supramolecular synthon binding to a transition-metal ion and fullerene (C60)

210

2,6-Cyclo-xenicanes from the brown algae Dilophus fasciola and Dilophus spiralis

211

2,6-Di(4-t-butylphenyl)phenyl-group 13 organometallic compounds

212

2,6-Di(pyrimidin-4-yl)pyridine Ligands with Nitrogen-Containing Auxiliaries: The Formation of Functionalized Molecular Clefts upon Metal Coordination

213

2,6-Diaryl-4-acylaminopyrimidines as potent and selective adenosine A2A antagonists with improved solubility and metabolic stability

214

2,6-Diaryl-4-phenacylaminopyrimidines as potent and selective adenosine A2A antagonists with reduced hERG liability

215

2,6-Diarylethynylanthracenes: synthesis, morphology, and electro-optical properties

216

2,6-Dibenzhydryl-N-(2-aryliminoacenaphthylenylidene)-4-chlorobenzenamino-palladium dichlorides: Synthesis, characterization, and use as catalysts in the Heck-reaction

217

2,6-Dibenzhydryl-N-(2-phenyliminoacenaphthylenylidene)-4-chloro-aniline nickel dihalides: Synthesis, characterization and ethylene polymerization for polyethylenes with high molecular weights

218

2,6-Dicarboxypyridinium chlorochromate: a mild, efficient, and selective reagent for oxidative deprotection of oximes to carbonyl compounds

219

2,6-Dicarboxypyridinium chlorochromate: an efficient and selective reagent for the oxidation of thiols to disulfides and sulfides to sulfoxides

220

2,6-Dichlorobenzonitrile, a cellulose biosynthesis inhibitor, affects morphology and structural integrity of petunia and lily pollen tubes

221

2,6-Difluorphenylxenon(II)bis(fluorsulfonyl)amid, -bis(trifluormethylsulfonyl)amid, -tris(fluorsulfonyl)methanid und -bis(trifluormethylsulfonyl)methanid—neue C–Xe–N- und C–Xe–C-Verbindungen?

222

2,6-Dimethoxyphenylphosphirane Oxide and Sulfide and their Thermolysis to Phosphinidene Chalcogenides—Kinetic and Mechanistic Studies

223

2,6-Dinitroaniline and β-cyclodextrin inclusion complex properties studied by different analytical methods

224

2,6-Diphenylphenolates of calcium, strontium and barium exhibiting π-phenyl encapsulation of the partially naked cations

225

2,6-Diphenylpyridine-based fluorophores: Synthesis, photophysical properties and effects of protonation

226

2,6-Diphenylpyridine-based organic emitter for electroluminescent device

227

2,6-Disubstituted N-arylsulfonyl piperidines as γ-secretase inhibitors

228

2,6-Disubstituted pyran-4-one and thiopyran-4-one inhibitors of DNA-Dependent protein kinase (DNA-PK)

229

2,6-Di-tert-butyl-4-diarylmethylene- 2,5-cyclohexadiene-1-thiones. First Isolable Unannelated Thioquinone Methides

230

2,6-pyridinedicarboxylic acid as an efficient and mild organocatalyst for the one-pot synthesis of xanthene derivative

231

2,6-Pyridinedicarboxylic acid as organocatalyst for the synthesis of 1,5-benzodiazepines through one-pot reaction

232

2,6-Quinolinyl derivatives as potent VLA-4 antagonists

233

2,7-Diazabicyclo[3.3.0]octanes as novel h5-HT1D receptor agonists

234

2,7-Dihydro-3H-pyridazino[5,4,3-kl]acridin-3-one derivatives, novel type of cytotoxic agents active on multidrug-resistant cell lines. Synthesis and biological evaluation Original Research Article

235

2,7-Dimethyl-3,8-dinitrodipyrazolo[1,5-a:1′,5′-d]pyrazine-4,9-dione: A new labelling reagent for liquid chromatographic analysis of amino acids Original Research Article

236

2,7-Disubstituted proton sponges as borderline systems for investigating barrier-free intramolecular hydrogen bonds. Protonated 2,7-bis(trimethylsilyl)- and 2,7-di(hydroxymethyl)-1,8-bis(dimethylamino)naphthalenes

237

2,7-Di-tert-butyl-Fmoc-P-OSu: A new polymer-Supported reagent for the protection of the amino group

238

2,8-Disubstituted adenosine derivatives as partial agonists for the adenosine A2A receptor Original Research Article

239

2,9-Dibromopentacene: Synthesis and the role of substituent and symmetry on solid-state order

240

2,9-Disubstituted-N6-(arylcarbamoyl)-8-azaadenines as new selective A3 adenosine receptor antagonists: Synthesis, biochemical and molecular modelling studies Original Research Article

241

2,μ(Ω) estimate to the mixed boundary value problem for second order elliptic equations and its application in the thermistor problem Original Research Article

242

2. A randomized, double-blind, multicentre crossover trial to evaluate in vivo inhibition of aromatase by Arimidex (ZD1033) (1 mg and 10 mg PO OD) in postmenopausal women with breast cancer

243

2. Changes in short afferent inhibition during phasic movement in focal dystonia

244

2. Comparison of the disinfection by-product formation potentials between a wastewater effluent and surface waters

245

2. Development and testing of an iPad application for teaching self-management to heart failure patients

246

2. Development of interictal spikes following status epilepticus from intrahippocampal pilocarpine

247

2. Dynamic analysis of EEG/MEG signals combined with fMRI

248

2. Economic assumptions underlying asian energy markets

249

2. Numerical Simulations of Water Flow and Solute Transport Applied to Acid Sulfate Soils

250

2. Pre-operative education – a review of the research design

251

2. Prognostic factors for the classification and staging of breast cancers

252

2. Receptors in HDL metabolism

253

2. Sensitized degradation of chlorophenols on iron oxides induced by visible light: Comparison with titanium oxide

254

2. Sex and intimacy among patients with implantable left-ventricular assist devices

255

2. Sleep-disordered breathing in heart failure; developing an evidence-based screening protocol

256

2. Somatosensory-evoked potential in patients with amyotrophic lateral sclerosis in a totally locked-in state

257

2. The influence of physical symptoms and mild cognitive impairment on heart failure self care

258

2. The IPC during the third revision period and beyond

259

2. THE RECONFIGURATION OF WORK AND EMPLOYMENT RELATIONS IN THE UNITED STATES AT THE TURN OF THE CENTURY

260

2. The response of a laboratory stream system to PCB exposure: study of periphytic and sediment accumulation patterns

261

2. The relationship between the satellite-based index and standard precipitation index, on different land covers

262

2.0 Å Resolution Crystal Structures of the Ternary Complexes of Human Phenylalanine Hydroxylase Catalytic Domain with Tetrahydrobiopterin and 3-(2-Thienyl)-l-alanine or l-Norleucine: Substrate Specificity and Molecular Motions Related to Substrate Binding

263

2.1 Maintaining walking direction when combining gaitwith vision distraction in young and elderly

264

2.1. Laboratory investigations in trigeminal neuralgia

265

2.10 Walking is more like catching than tapping: gait in the elderly as a complex cognitive task

266

2.11 A prospective study of older adults with a high level gait disorder: Evidence for a neurodegenerative process

267

2.1–1.85 Ga tectonic events in the Yangtze Block, South China: Petrological and geochronological evidence from the Kongling Complex and implications for the reconstruction of supercontinent Columbia

268

2.12 Gaze position, distance and postural stability in young and old subjects

269

2.13 Visual context affects postural strategies in healthy and labyrinthine deficient elderly

270

2.14 Effect of tactile ground surface indicators to the gait of elderly with normal vision

271

2.15 Age related changes in coping strategies to posturalthreat

272

2.16 Dynamic electromyographic activities of lower extremity muscles in patients with osteoarthritis of the knees

273

2.17 Dynamic control strategies used by older adults during obstacle avoidance

274

2.18 Center of mass (CoM) kinematics at slip onset and slip severity

275

2.19 The effect of age on dynamic postural equilibrium when stepping up

276

2.2 Performance based and self-reported postural control and functional correlates of stair climbing capacity

277

2.2. Spinothalamic nociceptive pathways

278

2.20 The role of vision in static posture control is age and task-dependent

279

2.21 Effects of protective equipment on the balancecontrol among younger and older firefighters

280

2.22 Postural balance in female and male subjects aged 8 to 93 years: A cross-sectional comparison

281

2.23 Effects of exercise and nutrition on Romberg quotient of postural balance in elderly with decreased bone mineral density

282

2.23 W diode-pumped Nd:YVO4/LBO Laser at 671 nm

283

2.24 The effect of postural sway on responses to anunexpected perturbation in young and elderly adults

284

2.25 Kinematic synergy adaptation to an unstable support surface and equilibrium maintenance in aging adults

285

2.26 The passive forward-push test can determine postural strategies

286

2.27 Controlling stability in challenging environments:Effects of ageing on modulation of rapid stepping reactions

287

2.28 Gaze behavior and the modulation of triggered stepping reactions to meet environmental demands in older adults

288

2.3 Vision influences on postural stability in different ages

289

2.3. Long-term depression of orofacial somatosensory processing

290

2.36 (mu)m diode pumped VCSEL operating at room temperature in continuous wave with circular TEM/sub 00/ output beam

291

2.4 GHz continuously variable ferroelectric phase shifters using all-pass networks

292

2.4 GHz direct-digital binary phase shift keying modulator using MEMS switch

293

2.4 Improving balance through imagery in frail elderly: Apilot study

294

2.4. Blink reflexes in orofacial pain conditions

295

2.41 W compact efficient CW blue light generation by intra-cavity frequency doubling of a compact Nd:YAG laser

296

2.45 GHz microwave plasma system for high-velocity thermal spraying

297

2.45 GHz synchronised polarised electron injection at MAMI

298

2.45 GHz synchronised polarised electron injection at MAMI

299

2.45-GHz-CMOS temperature compensated multi-controlled oscillator for IEEE 802.15 wireless PAN

300

2.4-in. monochrome small molecular OLED display for mobile application

301

2.5 BILLION LIVE WITH POOR SANITATION FACILITIES

302

2.5 Gbit/s silicon receiver OEIC with large diameter photodiode

303

2.5 GHz BaTiO3 DIELECTRIC RESONATOR ANTENNA

304

2.5 Kinematic and electromyographic analysis of rising from a chair during a “sit-to-walk” task in elderly subjects

305

2.5 MeV electron irradiation effect of alumina ceramics

306

2.5. The trigemino facial inhibitory reflex: Physiology, recording technique and topodiagnostic use

307

2.56-Tb/s (64*42.7 Gb/s) WDM transmission over 6000 km using all-Raman amplified inverse double-hybrid spans

308

2.5D Elastic graph matching

309

2.5D face recognition using Patch Geodesic Moments

310

2.5-D frequency-domain seismic wave modeling in heterogeneous, anisotropic media using a Gaussian quadrature grid technique

311

2.5-D gravity model of the Ni---Cu---PGM mineralized Mount Ayliff Intrusion (Insizwa Complex), South Africa

312

2.5-D Modeling in electromagnetic methods of geophysics

313

2.5D modelling of Somma–Vesuvius structure by aeromagnetic data

314

2.5-D Numerical Simulation of Acoustic Wave Propagation

315

2.5D scattering of waves by rigid inclusions buried under a fluid channel via BEM

316

2.5-Year-olds use cross-situational consistency to learn verbs under referential uncertainty

317

2.6 Å Resolution Crystal Structure of Helices of the Motile Major Sperm Protein (MSP) of Caenorhabditis elegans

318

2.6 The elderly combat to strive for better physical health

319

2.6. The role of the brain stem in central sensitisation in humans

320

2.61 (mu)m GaInAsSb/AlGaAsSb type I quantum well laser diodes with low threshold

321

2.61 Ga potassic granites and crustal reworking in the western Dharwar craton, southern India: Tectonic, geochronologic and geochemical constraints

322

2.7 Effect of age on movement amplitude and frequencyduring heel-toe rocking

323

2.7 μm fluorescence and energy transfer in Er3+ doped germanosilicate glasses

324

2.7. Bilateral brainstem activation by noxious thermal stimulation in the face

325

2.8 Å crystal structure of the malachite green aptamer

326

2.8 Challenges to whole-body stability during turning in older adults

327

2.8 Ga Old Anorogenic Granite-Acid Volcanics Association from Western Margin of the Singhbhum-Orissa Craton, Eastern India

328

2.85 µm fluorescence of Ho-doped water-free fluorotellurite glasses

329

2.9 Functional capacities evaluation during simulate working task

330

2.C.4 Dietary fatty acids and the prevention of cardiovascular disease

331

2.C.6 New strategies for drugs in atherosclerosis

332

2.E.1 Fish oil, lipids and coronary disease

333

2.Endothelin antagonists: Evaluation of 2,1,3-benzothiadiazole as a methylendioxyphenyl bioisoster

334

2.P.1 Selective uptake of HDL-CE by human adipose tissue is an LRP-dependent process

335

2.P.10 Effects of erythromycin on plasma fluvastatin levels: A pharmacokinetic study

336

2.P.100 The in vivo of metabolism of free-Apo(a) in normals and subjects with abetalipoproteinemia

337

2.P.101 Effect of gamma radiolysis-induced oxidation of lipoprotein(a) on plasminogen activator inhibitor (PAI-1) secretion by endothelial

338

2.P.102 Nicotinic acid decreases specifically plasma Lp(a) in cynomolgus monkeys without affecting other lipoproteins

339

2.P.103 Immunoquantification of lipoprotein (a): A comparative evaluation of four methods

340

2.P.104 Effect of continuous combined estrogen-progestin therapy on lipoprotein (a) and lipid metabolism

341

2.P.105 Apo (a) phenotypes and Lp(a) levels in acute coronary syndromes

342

2.P.106 Lp(a) and cholesterol act synergistically and predict primary myocardial infarction in Swedish males

343

2.P.107 The importance of Lp(a) as a risk factor for coronary heart disease in black and white US women

344

2.P.108 Effects of losartan on blood pressure, microalbuminuria, insulin sensitivity and lipid profile in hypertensive type II diabetics with microalbuminuria

345

2.P.109 Lack of effect of acute and chronic normalization of plasma growth hormone concentration on lipoprotein (a) levels in patients with acromegalia

346

2.P.11 Effects of atorvastatin on intracellular levels and stability of apolipoprotein B and HMG-CoA reductase in Hep G2 cells

347

2.P.110 Reduction of Lp(a) by LDL-immunoadsorption

348

2.P.111 Elevated lipoprotein (a) levels and coronary heart disease: Differences between non-insulin-dependent diabetic patients and nondiabetic subjects

349

2.P.112 Urinary excretion of lipoprotein(a) and apolipoprotein(a) in nephrotic patients

350

2.P.114 Lp(a) levels in patients with mild/moderate renal failure

351

2.P.115 Apolipoprotein(a) phenotypes as a predictor of occlusions in coronary arteries

352

2.P.116 Alcohol consumption, lipoprotein(a) and hormonal status in middle-aged black African males

353

2.P.117 Is the measurement of unbound apo(a) of diagnostic interest?

354

2.P.118 The impact of heat shock proteins as a risk factor for coronary heart disease

355

2.P.119 The KIV-10 Asp57 → Thr mutation in chimpanzee apo(a) abolishes fibrin binding

356

2.P.12 Inhibitors of hydroxymethyl glutaryl-CoA reductase as modulators of intimal thickening in diet-induced atherosclerosis

357

2.P.120 Identification of kringles of apolipoprotein(a) that enable its binding to fibrin and monocytic cells

358

2.P.121 Binding of apo(a) isoforms to fibrin is modified by their incorporation into an LDL lipoparticle

359

2.P.122 Elevated level of lipoprotein(a) and severity of coronary artery disease in non-diabetic patients

360

2.P.123 Treatment of hyperlipoproteinemia (a) with LDL-apheresis in order to stop progredient coronary heart disease: A case report

361

2.P.124 Effectiveness of the whole blood adsorber system dali in the treatment of hyperlipoproteinemia(a)

362

2.P.125 The effects of body weight loss on lipoprotein(a) in obese Japanese middle-aged women

363

2.P.126 Studies of the 5′-region of the apolipoprotein(a) gene in HepG2 cells by luciferase reporter gene assays

364

2.P.127 Red wine consumption: Another antiatherogenic effect related to decreased lipoprotein(a) levels

365

2.P.128 Recombinant apolipoprotein(a) and lipoprotein(a) enhance platelet responses to a thrombin receptor-activating peptide

366

2.P.129 Urinary excretion of apo(a) fragments in non insulin dependent diabetes mellitus patients

367

2.P.13 Effect of lovastatin in hyperlipoproteinaemic patients

368

2.P.130 Urinary excretion of apo(a) in patients after kidney transplantation

369

2.P.131 Demonstration of covalent binding of lipoprotein(a) [Lp(a)] to fibrin and human umbilical vein endothelial cells (HUVEC)

370

2.P.132 A fibrin-binding method for the functional identification of lipoprotein(a) in plasma from patients with cardiovascular disease

371

2.P.133 Lp(a) levels and apo(a) phenotypes in angiographically established coronary heart disease and in controls

372

2.P.134 Synthetic regulation of lipoprotein(a) in monkey hepatocytes

373

2.P.136 Serum lipoprotein(a) and ultrasonographic findings of carotid plaques

374

2.P.137 Increased degradation of lipoprotein(a) in atherosclerotic compared with nonlesioned aortic intima-inner media: In vivo evidence that lipoprotein(a) may contribute to foam cell formation

375

2.P.138 Increased levels of Lp(a) in nephrotic syndrome of children is related to hypoalbuminemia, not to proteinuria

376

2.P.139 Effects of oral isotretinoin (13-cis retinoic acid) on lipoprotein(a) and HDL subclasses lpA-I and lpA-I: A-II in healthy volunteers

377

2.P.14 An overview of the clinical safety profile of atorvastatin a new, more effective HMG-CoA reductase inhibitor

378

2.P.140 Lp(a) secretion is enhanced by incubation of cynomolgus monkey hepatocytes with retinoic acid

379

2.P.141 Screening for mutations in the apolipoprotein(a) unique kringles type 6, 9 and 10

380

2.P.142 Prevalence of atherosclerotic vascular disease in the pedigrees with high Lp(a)

381

2.P.143 Lipoprotein (a) metabolism in patients with heterozygous familial hypercholesterolemia

382

2.P.144 Lp(α) levels during acute infections

383

2.P.145 Lipoprotein(a) concentration and apolipoprotein(a) isoform size in young patients with stroke

384

2.P.146 Differentiation of plasma lipoprotein (a) in a population of 1989 Greek army recruits

385

2.P.147 Lp(a) apheresis new approach for specific Lp(a) lowering

386

2.P.148 Lp(a) levels in an heterogeneous sample of subjects with familial hypercholesterolemia

387

2.P.149 Uptake of lipoprotein(a) by mouse embryonic fibroblasts via the LDL-receptor and/or the LDL receptor-related protein

388

2.P.15 Two-year comparison of safety and efficacy of atorvastatin and lovastatin

389

2.P.150 The carotid artery stenosis and the Lp(a) serum concentration: A correlation analysis

390

2.P.151 Lipoprotein(a) concentrations in subjects with one and two apolipoprotein(a) isoforms

391

2.P.152 Physical exercise decreases lipoprotein(a) levels in hyper-lp(a) diabetic patients

392

2.P.154 Lack of impaired endothelium-dependent vasorelaxation in aortas isolated from transgenic mice expressing human apolipoprotein(a)

393

2.P.155 Cholesterol esterification in hypercholesterolemic and normolipidemic subjects: Effects of simvastatin

394

2.P.156 Lipoprotein(a) levels in pulmonary arterial hypertension

395

2.P.157 Apolipoprotein(a) phenotype and serum Lp(a) levels in patients with angina pectoris and myocardial infarction

396

2.P.158 The effects of Lipoprotein (a) on endothelial function

397

2.P.159 The role of Lp(a) in the development of coronary artery disease seems to be age dependent

398

2.P.16 Fluvastatin inhibits free radical-initiated oxidation of LDL and erythrocyte hemolysis in vitro

399

2.P.160 A comparison of lipoprotein (a)-cholesterol levels and sinking prebeta lipoprol with heart disease risk in the Framingham heart study

400

2.P.161 Effect of glyated lipoprotein(a) on the production of fibrinolytic regulators in vascular endothelial cells

401

2.P.162 Relation of 5′-flanking region of the apolipoprotein(a) gene to serum lipoprotein(a) level

402

2.P.163 Localization of Lp(a) gene in human chromosomes by in situ hybridization with digoxigenin-labeled probe

403

2.P.164 Transcriptional regulation of apolipoprotein(a) synthesis by insulin

404

2.P.165 Lipoprotein(a) is a potent chemoattractant selective for human peripheral monocytes

405

2.P.166 Elevated lipoprotein(a) levels in patients with myocardial infarction are not fully determined by variation at the apo(a) gene locus. The ECTIM study

406

2.P.167 Discrepancy between whole blood and plasma concentrations of Lp(a)

407

2.P.168 Low HDL cholesterol and low lipid standardized vitamin E are the best determinants of lipid risk in our coronary patients

408

2.P.169 Detection of serum lipoprotein(a) by agarose gel electrophoresis

409

2.P.17 Effectiveness of atorvastatin in treating patients to LDL-C goals compared with lovastatin, pravastatin and simvastatin

410

2.P.170 Nandrolone decanoate reduces lipoprotein(a) levels without effect on other lipid parameters

411

2.P.171 Effect of repeated Lp(a) apheresis on metabolic parameters of lipoprotein(a)

412

2.P.172 Effect of dietary pattern on serum lipoprotein parameters in young families

413

2.P.173 Evaluation of the risk factors in coronary artery disease in Egypt. Evolving data from the national project: Lipid Profile among Egyptians (L.P.E)

414

2.P.174 Apolipoproteins and lipoprotein particles level in Moroccan patients with previous myocardial infarction

415

2.P.175 Carotid atherosclerosis and vascular risk factors in patients attending an Italian Lipid Clinic

416

2.P.176 Management of low-density lipoprotein cholesterol for secondary prevention of cardiac event after myocardial infarction

417

2.P.177 High level homocysteine, LDL modification and CHD

418

2.P.178 Smoking and transvascular leakage of albumin: Preliminary findings

419

2.P.179 Towards a cellular basis for mild hyperhomocysteinemia: Methionine metabolism in cultured human peripheral blood cells

420

2.P.18 Comparison of the efficacy and safety of atorvastatin with simvastatin in patients with primary hypercholesterolemia

421

2.P.180 Prognostic value of raised soluble thrombomodulin and soluble E-selectin in ischaemic heart disease

422

2.P.181 Lipids atherogenic factors in patients on haemodyalysis

423

2.P.182 Low density lipoprotein-associated phospholipase A2 (LDL-PLA2) as a risk factor for coronary artery disease

424

2.P.183 Microalbuminuria in dislipidaemic subjects

425

2.P.184 Fibrinolytic parameters and insulin sensitivity index related to fasting and postprandial triglyceride (TG) in healthy “normolipemic” subjects

426

2.P.185 Coronary heart disease risk factor clustering among three French regions: The WHO-MONICA population study

427

2.P.186 Influence of endurance training on susceptibility of LDL to oxidation

428

2.P.187 Methylenetetrahydrofolate reductase gene and carotid artery structural and functional characteristics in asymptomatic subjects

429

2.P.188 Pro-thrombotic effects of an acute methionine load-induced hyperhomocysteinemia in rats

430

2.P.189 Hyper-HDLemia in renal transplant recipients: Mechanisms and significations

431

2.P.19 The short-term effects of atorvastatin on lipid levels in patients with hyperlipidemia

432

2.P.190 Dyslipidaemias in children and adolescents in Portugal: A public health problem

433

2.P.191 Lipoproteins and homocysteine as risk markers for mortality in patients with coronary artery disease (CAD)

434

2.P.192 Lack of adequate risk factor management in patients with coronary artery disease

435

2.P.193 The current management of cardiovascular risk factors does not match the severity of risk factors and clinical guidelines

436

2.P.194 Coronary risk profile in Brazil

437

2.P.195 Gender differences in prediction of coronary artery disease (CAD) by plasma lipoproteins, LCAT measurements

438

2.P.196 LP(a), PAI-1 and fibrinogen are predictors of severe carotid atherosclerosis in young individuals

439

2.P.197 How many patients with coronary artery disease exhibit a significant lipid disorder in a department of cardiology in France?

440

2.P.198 Sitostanol ester added to long term simvastatin treatment of coronary patients with low and high basal cholesterol absorption

441

2.P.199 Significance of insulin like growth factor 1 for macro- and microangiopathy in non-insulin-dependent diabetes mellitus

442

2.P.2 The composition and structure of HDL regulate plasma clearance kinetics in rabbits

443

2.P.20 HMG-CoA reductase and ACAT inhibitors act synergistically to lower plasma cholesterol and limit atherosclerotic lesion formation in the rabbit

444

2.P.201 Does the fitness influence plasma lipoprotein levels?

445

2.P.202 Correlation between the concentrations of plasma homocysteine and vitamin B6, B12, and folate in end stage renal disease

446

2.P.203 Relation of cigarette smoking to other cardiovascular risk factors in the general population of Singapore

447

2.P.204 Homocysteine, recurrent cardiac events, and the methylenetrarahydrofolate thermolabile mutation in coronary artery disease patients

448

2.P.205 The assessment of determinants of cardiovascular risk factor clustering by multiple regression analysis

449

2.P.206 Hyperhomocysteinaemia attributes to 10 percent of all cardiovascular disease in a 50–75 year-old Caucasian population

450

2.P.207 Elevated levels of plasma homocysteine related to atherosclerotic lesions of vein grafts after coronary artery bypass grafts (CABG)

451

2.P.208 Associations between triglycerides and cholesterol levels and myocardial infarction: Results of the Tunisian study

452

2.P.21 The HMG-CoA reductase inhibitors atorvastatin and lovastatin reduce accumulation of collagenase and 92-kD gelatinase released by cultured human monocytic and vascular smooth muscle cells

453

2.P.210 Family screening as an effective tool to prevent early cardiovascular events

454

2.P.211 Plasma homocysteine levels and premature coronary artery disease in male patients

455

2.P.212 Short stature and heart disease: Nature or nurture?

456

2.P.213 Age-trends of lipid profile in Novosibirsk population

457

2.P.214 Lipid and hemostatic risk factors of coronary insufficiency in syndrome X

458

2.P.215 Hyperinsulinemia and cardiovascular mortality

459

2.P.216 To assess the changes in cardiovascular risk profile after one year of intervention at a worksite

460

2.P.217 MTHFR thermolability and vitamin status in the pathogenesis of hyperhomocysteinemia in coronary artery disease subjects

461

2.P.218 Is a fasting plasma homocysteine measurement an adequate screen for hyperhomocysteinemia?

462

2.P.219 Homocysteine and carotid artery atherosclerosis

463

2.P.22 Efficacy and safety of fluvastatin in patients with non insulin dependent diabetes on insulin therapy and dyslipidemia

464

2.P.220 Serum fibrinogen and lipoprotein(a) in a Portuguese NIDDM population

465

2.P.222 Coronary heart disease risk factors and carotid atherosclerosis in a high risk Hungarian population

466

2.P.223 Hyperfibrinogenemia and hypertriglyceridemia influence the histocytologic composition of atherosclerotic carotid plaques

467

2.P.224 Hyperhomocyst(e)inemia as an emerging risk factor of atherosclerotic vascular diseases

468

2.P.225 Effect of vitaminic therapy in hyperhomocysteinemic patients

469

2.P.226 Serum lipids in hyperhomocysteinemic patients

470

2.P.227 Frequencies of factor VII gene polymorphism and the relation to serum triglycerides in patients with chronic disease

471

2.P.228 Characteristics changes in coronary artery in patients with hypothyroidism and myocardial infarction

472

2.P.229 Hyperhomocysteinemia is a risk factor for ischemic heart disease in diabetic patients

473

2.P.23 A comparative study on the effects of fluvastatin and simvastatin on serum lipoproteins in hypercholesterolemic patients

474

2.P.230 Fractional esterification rate of cholesterol in HDL can predict the particle size of LDL and HDL in CHD patients

475

2.P.232 Lipids, LP(α) and fibrinogen in acute stroke episodes

476

2.P.233 Oxygen free radicals generation by granulocytes of patients with atherosclerosis

477

2.P.234 Risk factors for thoracic aortic atherosclerosis. A prospective study using multiplane transoesophageal echocardiography

478

2.P.235 Serum paraoxonase activity and early atherosclecrosis in hypertensive and hypercholesterolemic patients

479

2.P.236 A gas chromatography/mass spectrometry method for the quantitation of total homocysteine in human plasma

480

2.P.237 Cardiovascular risk factors in peripheral arterial disease patients with and without previous history of coronary artery disease

481

2.P.239 Lp(a) as a possible biochemical marker for vein graft stenosis after coronary artery bypass surgery

482

2.P.24 Responses to the inhibition of HMG-CoA reductase: A comparison of simvastatin and atorvastatin

483

2.P.240 Coronary heart disease risk in middle aged population - 10 year Warsaw Pol-MONICA follow-up project

484

2.P.241 Dependence between the advancement of the ischemic heart disease and the HDL cholesterol subfraction

485

2.P.243 Self-reported physical activity in healthy children is correlated with cardiovascular risk factors

486

2.P.244 Relatinship between plasma endothelin-1, HDL-C and systolic blood pressure in renal transplant recipients

487

2.P.245 Prospective randomized atherosclecrosis intervention trial in children The STRIP project

488

2.P.246 Methylentetrahydrofolate reductase genotypes in young survivors of myocardial infarction

489

2.P.247 Insulin resistance and homocystein - is there any relationship?

490

2.P.248 A prospective study of lipoprotein factors in patients with unstable angina and acute myocardial infarction

491

2.P.249 Lipoprotein metabolism in patients with coronary artery disease and its relationship with myocardial infarction

492

2.P.251 Coronary risk factors in subjects with familial hypercholesterolemia in Spain

493

2.P.252 HDL-cholesterol after surgery for aorto-coronary grafts

494

2.P.253 Common risk factors of atherosclerosis are independent from the insertion/deletion angiostensin converting enzyme gene polymorphism in subjects with coronary heart disease and healthy controls

495

2.P.254 Changes of lipid levels in Korean population

496

2.P.255 Atherosclerosis risk factors and nutrition of male students with the paternal premature myocardial infarction

497

2.P.256 Comparison of Brazilian men and women at high risk of vascular disease

498

2.P.257 Sensitivity of platelets to nitrix oxide is attenuated after vigorous exercise

499

2.P.259 Attitudes towards coronary risk factor reduction: The HELP study

500

2.P.26 Efficacy and safety of one-year treatment with slow-release nicotinic acid. Monitoring of drug concentration in serum

501

2.P.260 Independent effect of hyperglycaemia on coronary heart disease mortality among non-insulin dependent diabetic subjects: The Reykjavik study

502

2.P.261 The importance of lipid status in coronary heart disease

503

2.P.262 The assessment of risk of myocardial infarction in Moscow population

504

2.P.263 Twenty years lasting interventional study of cardiovascular risk factors in middle age men

505

2.P.264 A common mutation in methylenetetrahydrofolate reductase: Associations with homocysteine and risk of coronary atherosclerosis

506

2.P.265 Effects of androgenic anabolic steroids (AAS) on apolipoproteins and lipoprotein(a)

507

2.P.266 Serum angiotensin convertase activity in men after myocardial infarction and their healthy sons

508

2.P.268 Aging, smoking and hypercholesterolaemia have a less impact on endothelial function in the Chinese than Caucasian

509

2.P.269 Higher 7β-hydroxycholesterol in high cardiovascular risk population

510

2.P.27 Regulation of the growth kinetics of a promyelocitic leukemia cell line by hydroxymethyl glutaryl CoA-reductase

511

2.P.270 Lower oxidizability of LDL in elderly subjects with no evidence of carotid atherosclerosis

512

2.P.271 High plasma Lp(a) levels and low plasma HDL-cholesterol levels as risk factors for cerebrovascular disease in elderly men and women

513

2.P.272 Genetic risk factors in the elderly: Studies in the apolipoprotein E gene and in the methylenetetrahydrofolate reductase gene

514

2.P.273 The importance of hyperhomocysteinemia in high age people

515

2.P.275 Secondary prevention is the main basis of elderly referrals to a lipid clinic

516

2.P.276 Polymorphism of ApoAIV, apo(a) and Lp(a) plasma levels in centenarians

517

2.P.276 Polymorphism of ApoAIV, apo(a) and Lp(a) plasma levels in centenarians

518

2.P.277 One year experience with simvastatin in patients over 65 with primary hypercholesterolemia

519

2.P.278 Mild hyperhomocysteinemia correlated to folate status in Italian centenarians

520

2.P.279 Cardiovascular risks factors in a Pireness geriatric population

521

2.P.28 Preclinical drug metabolism studies in rat, mouse, dog and monkey with allometric scaling for CP-340,868, a novel squalene synthetase inhibitor

522

2.P.280 Serum sialic acid in elderly

523

2.P.285 Effects of the hormonal replacement therapy on plasma lipids in postmenopausal women with type II hyperlipidemia

524

2.P.286 Rationale and design of a trial to evaluate the impact of continuous combined hormone replacement therapy on the cardiovascular disease risk profile

525

2.P.287 Homocysteine is an independent determinant of plasma endothelin levels in healthy postmenopausal women

526

2.P.288 Postmenopausal increment of free and esterified cholesterol in the intima media of uterine arteries

527

2.P.289 Hormone replacement therapy: Can usage influence clinical outcome following coronary balloon angioplasty?

528

2.P.29 Effect of fluvastatin on plasma free-oxygen radicals (FOR) concentrations and on lipidaemic profile in patients with coronary artery disease (CAD)

529

2.P.290 Changes of lipid levels with menopause in women

530

2.P.291 Effects of tibolone on lipoproteins

531

2.P.292 The influence of menopause on LDL-subclass distributions, LDL-oxidizability and Lp(a) concentrations

532

2.P.293 Menopause aggravates postprandial lipemia

533

2.P.294 Effects of soy on lipoproteins in postmenopausal women: A double blind, multicentre, placebo-controlled trial

534

2.P.295 Does early menopause affect the risk of atherosclerosis?

535

2.P.296 The effect of hormone replacement therapy on hemostatic parameters in peri- and postmenopausal women

536

2.P.297 Lipid effects of adding C-19 versus C-21 progestin to conjugated estrogen in postmenopausal women

537

2.P.298 Current state of serum lipid levels in the general Japanese population - cholesterol and lipoprotein(a)

538

2.P.299 Effects of tamoxifen on lipid profile in postmenopausal women

539

2.P.3 Lipid-free apolipoprotein A-I can act as a shuttle to promote cholesterol efflux to apolipoprotein A-I-containng lipoproteins

540

2.P.30 Effect of fluvastatin on coagulant-fibrinolytic system in patients with coronary artery disease

541

2.P.300 Social strata and menopause caused changes in the cardiovascular risk profile

542

2.P.301 Estrogen/progestine replacement therapy improves the course of coronary artery disease in menopausal women

543

2.P.302 Smaller LDL particle size in women with polycystic ovary syndrome as compared to controls

544

2.P.303 Serum lipoprotein profile in women with coronary heart disease

545

2.P.304 17 β estradiol retard the progression of severe atherosclerosis induced by high cholesterol diet plus baloon injury: The relation of NO

546

2.P.305 Preliminary analysis of tamoxifen-induced lipemia

547

2.P.306 Hypercholesterolemia in the middle-age woman is individually a cause of ventricular arrhythmia

548

2.P.307 Gender does not predict adverse acute outcome following coronary balloon angioplasty

549

2.P.308 Lipoprotein(a), apolipoprotein E and hormonal profile in menstruating women after myocardial infarction

550

2.P.309 Effects of female sexual hormones on contractility and morphology of pre- and postmenopausal human uterine arteries

551

2.P.31 Reduction of egg yolk cholesterol content through inhibition of hepatic cholesterol biosynthesis and alteration of plasma VLDL composition in laying hens: Comparative effects of atorvastatin, lovastatin, and simvastatin

552

2.P.310 The evaluation of the atherogenic risk factors in pregnant women

553

2.P.311 Endogenous sex hormones and carotid atherosclerosis in women participating to a population-based study: Findings from Progetto Atena

554

2.P.312 Nitric oxide bioactivity in premenopausal women on hormonal contraceptives

555

2.P.313 The effect of raloxifene on markers of cardiovascular risk in healthy, post-menopausal women

556

2.P.314 Platelet aggregation induced by a monoclonal antibody to von Willebrand Factor

557

2.P.315 Simvastatin effect on platelet activity in patients with familial hypercholesterolaemia

558

2.P.316 Flow cytometry analysis of platelets in whole blood from unstable angina patients

559

2.P.317 Platelet size, β-thromboglobulin and serotonine concentration in patients with essential hypertension

560

2.P.318 Platelets count, morphology and aggregation in patients with familian hypercholesterolaemia

561

2.P.319 Effects of normothermic versus hypothermic cardiopulmonary bypass on cytokine production and platelet function

562

2.P.32 Comparison of cerivastatin and gemfibrozil in the treatment of primary mixed hyperlipidemia

563

2.P.320 Alkyl phosphatidylcholine core aldehydes exist in human atheromas and induce platelet aggregation through PAF receptor

564

2.P.321 Smoking, platelets and risk of thrombosis

565

2.P.322 The influence of butter and vegetable oil loadings on the state of thrombocyte membranes in patients with ischemic heart disease (IHD)

566

2.P.323 Structural and functional organisation of thrombocyte membranes in patients with ischemic heart disease (IHD) depending on menʹage

567

2.P.324 Immunolocalization of blocked and unblocked GP IIb-IIIa complexes in platelets during antithrombotic therapy with c7E3 Fab (ReoPro, abciximab)

568

2.P.325 CD36 is a specific platelet receptor for native and modified low-density lipoproteins

569

2.P.326 Short-term heterologous desensitization of platelet LDL receptor by high lipoprotein levels

570

2.P.326 Thyroid hormones as a determinant of plasma D-dimers levels in hyperlipidemic patients

571

2.P.327 Platelet αIIb-β3 integrin or glycoprotein (GP) IIb-IIIa complex are not related to platelet HDL3 binding

572

2.P.328 Long-term desensitization of platelet LDL receptor by high VLDL levels. Effects of gemfibrozil treatment

573

2.P.329 Hydrogen peroxide involvement in platement activation induced by collagen

574

2.P.33 Long-term extension of the comparison of cerivastatin and gemfibrozil in the treatment of primary mixed hyperlipidemia

575

2.P.330 Platelet behavior in whole blood with enhanced HDL concentration

576

2.P.331 The ADP-activated non selective cation channels may have a role in platelet aggregation

577

2.P.332 Relationship between reduction of plasma cholesterol and increased platelet activity in hypercholesterolemia

578

2.P.333 Evidence for th erole of adenosine diphosphate in platelet aggregation by remnant like lipoprotein particles of human plasma very low density lipoproteins and chylomicrns

579

2.P.334 ADP induces transient refractoriness of platelet adhesion to subendothelium under flow conditions

580

2.P.335 Colony-forming units-megakaryocytes (CFu-MEG) and primary hyperlipidemia

581

2.P.336 Native microaggregates and spontaneous platelet aggregation may present a platelet susceptibility leading to thrombogenesis - detection with an original method using a novel platelet aggregometer employing a laser light scattering

582

2.P.337 Secretion of PAF-acetylhydrolase activity during platelet aggregation in patients undergoing coronary angioplasty

583

2.P.338 Role of homocyst(e)ine in platelet aggregation

584

2.P.339 Impaired inhibition by insulin of ADP-induced expression of platelet fibrinogen receptor in NIDDM patients

585

2.P.34 Long-term efficacy and safety of a combined fluvastatin-fenofibrate therapy in primary hypercholesterolemia

586

2.P.340 Inhibition of the procoagulant activity of thromboplastin by apolipoprotein B-100

587

2.P.341 Effect of dietary saturated, oleic and n-3 fatty acids on acute collagen-induced thrombus formation in rats

588

2.P.342 Effect of policosanol on platelet aggregation and serum levels or arachidonic acid metabolites in healthy volunteers

589

2.P.343 Fluvastatin reduces platelet activity in vitro

590

2.P.344 Platelet function in hypercholesterolemia - importance of combine hyperlipidemia

591

2.P.345 The role of the C-terminal of tissue factor pathway inhibitor (TFPI) in inhibition of the extrinsic pathway of coagulation

592

2.P.347 Plasminogen activator inhibitor-1 in human fat: Effect of tumor necrosis factor-α and pentoxifylline

593

2.P.348 Alpha fibronogen genotype is associated with the porosity and density of the fibrin gel matrix in MI patients

594

2.P.349 Protein S deficiency as an additional risk factor for juvenile TIA

595

2.P.35 Lipid-lowering effect of atorvastatin in homozygous familial hypercholesterolemia patients with portocaval anastomosis

596

2.P.350 A therapeutic dosage (3 g/day) of borage oil supplementation has no effect on platelet aggregation in healthy volunteers

597

2.P.351 Lysophosphophatidycholine inhibits tissue factor expression

598

2.P.352 Low or medium dose acetylsalicylic acid increases fibrin gel porosity is healthy adults

599

2.P.353 PAI-1 genotype, PAI-1 level and risk of thrombotic complications after renal transplantation

600

2.P.354 The factor V leiden (R506Q) mutation and risk of thrombosis in renal transplant recipients

601

2.P.355 Protease-activated receptor genes are clustered on 5q13

602

2.P.356 Fibrinogen synthesis in chronic smokers is significantly reduced after short-term cessation from smoking

603

2.P.357 The effects of physiological meals containing structured triglycerides with different fatty acid compositions on postprandial haemostasis

604

2.P.358 Prognostic value of haemorheological, haemostatic and fibrinolytic changes in progressing of cerebrovascular disorders

605

2.P.359 Is plasma fibrinogen before heart transplantation an independent predictor of graft vessel disease?

606

2.P.36 The efficacy of once-nightly niacin (Niaspan) on lipoproteins in dyslipidemic patients

607

2.P.360 Lipo-Merz reduces levels of fibrinogen and factor VII in patients with arterial hypertension

608

2.P.361 Nicotinic acid lowers P-fibrinogen and stimulates fibrinolysis!

609

2.P.363 Effects of long term administration of eicosapentaenoic acid on serum levels of tissue plasminogen activator and its inhibitor

610

2.P.364 Myocardial fibrin deposits in first month after transplantation predict subsequent coronary artery disease in cardiac allograft recipients

611

2.P.365 Coronary heart disease is associated with alterations in the daytime fluctuation pattern of plasminogen activator inhibitor 1 levels both in non-insulin-dependent diabetes patients and in nondiabetic subjects

612

2.P.366 High prevalence of homozigosity for the 677C → T mutation of the 5;10-methylenetetrahydrofolate reductase gene and hyperhomocysteinemia in patients with early-onset thrombotic events

613

2.P.367 Protection of exercise induced pro-thrombosis by aspirin

614

2.P.368 Factor VII: A responds to fatty meals, independently of fat composition

615

2.P.369 Procoagulant factors and cholesterol

616

2.P.37 Fenofibrate decreases the fibrinogen contents depending on its basal plasma levels in patients with hyperlipidemia

617

2.P.370 Effect of simvastatin treatment on thrombin generation in marked hypercholesterolemia

618

2.P.371 In vivo thromboxane/prostacyclin balance unfavourable affected in humans after diets rich in stearic acid or trans fatty acids

619

2.P.372 Contribution of fibrinogen to elevated plasma viscosity in patients with familial hypertriglyceridemia

620

2.P.373 Different effects of wine and red wine polyphenols on PAI-1 in healthy men

621

2.P.374 Changes of blood rheology by lipid oxidation as risk factor for thrombosis

622

2.P.375 Tissue factor pathway inhibitor inhibits aortic smooth muscle cell migration induced by tissue factor/factor VIIa complex

623

2.P.376 Effect of hirulog-1 on fibrinolysis and platelet deposition

624

2.P.377 Collagen-targeted antibodies could prevent acute thrombosis following PTCA

625

2.P.378 Correlation of haemostatic variables and structural changes of major arteries of the head in ischemic stroke patients

626

2.P.379 D-Dimers and fibrinogen in patients with left ventricle-dysfunction after myocardial infarction and in generalized atheriosclerosis

627

2.P.38 Long-term effects of low dose Omacor® in patients with severe hypertriglyceridemia

628

2.P.380 GPIIbIIIa inhibitors reduce procoagulant activity of platelet-derived microparticles (MP) by inhibiting their formation but not binding to fibrin(ogen)

629

2.P.381 A common mutation (G−455 → A) in the β-fibrinogen promoter is an independent predictor of plasma fibrinogen, but not of ischemic heart disease. A study of 9,127 individuals based on the Copenhagen City Heart Study

630

2.P.382 Fibrinolytic indicators inplasma and the generation of vascular plasmin in human arteriosclerosis

631

2.P.383 Aspirin-like effects of wine polyphenols on platelet aggregation in healthy men

632

2.P.39 Effect of bezafibrate on atherogenic lipoproteins in Japanese familial combined hyperlipidemic patients with or without impaired glucose tolerance

633

2.P.4 Expression of the human phospholipid transfer protein by the yeast Pichia pastoris

634

2.P.40 Discovery of the squalene synthetase inhibitor CP-340,868

635

2.P.41 Two year treatment experience with high dose atorvastatin

636

2.P.42 An overview of the clinical efficacy profile of atorvastatin

637

2.P.43 Mechanisms of pravastatin effects on plasma lipoprotein subfractions, estimated by activities of LCAT, CETP and lymphocyte LDL-receptor

638

2.P.44 Can fluvastatin be effectively used in the treatment of combined hyperlipidemia?

639

2.P.45 Targeting high risk patients with hypercholesterolemia: The efficacy and safety of simvastatin 80 mg/d

640

2.P.46 Associations of changes in blood lipids and hemostatic factors during fenofibrate treatment in dyslipidemic patients with polymetabolic syndrome (PMS)

641

2.P.47 Is there an effect of defined molecular defect on therapeutic response to HMG Co A reductase inhibitors in patients with familial hypercholesterolaemia?

642

2.P.48 Lipid-regulating effects of new classes of squalene epoxidase inhibitors

643

2.P.49 KY-455, a new bioavailable ACAT inhibitor with anti-peroxidative activity

644

2.P.5 In vitro factors affecting the concentration of gamma-LpE (γ-LpE) in human plasma

645

2.P.50 Niacin, by inhibiting both fatty acid synthesis and triacylglycerol formation, augments apo B degradation in Hep G2 cells

646

2.P.51 Escape phenomenon during the long-term administration of pravastatin for phyperlipideia associated with diabetes

647

2.P.52 Comparison of type II hyperlipoproteinemic patients with apoprotein E2, E3, and E4 phenotypes with respect to the response of plasma levels of lipids and apoproteins to simvastatin

648

2.P.53 Effects of long-term (for 5 years) treatment using pravastatin sodium on hyperlipidemia in diabetics

649

2.P.54 A two-year intensive lipid lowering in patients with familial hypercholesterolemia

650

2.P.55 ACAT inhibition by CI-1011 lowers plasma triglycerides in rats by enhancing the clearance of VLDL

651

2.P.56 Ciprofibrate in the treatment of hypertensive postmenopausal women with hyperlipidaemia IIa

652

2.P.57 Effect of atorvastatin on key enzymes regulating lipid metabolism in the cholesterol/coconut oil fed rabbit

653

2.P.58 Effects of atorvastatin on endothelium-dependent relaxations and contractions in dyslipidemic rabbits

654

2.P.59 Efficacy and safety of cerivastatin, a novel potent HMG-CoA reductase inhibitor, in primary hypercholesterolaemia: A comparative study

655

2.P.6 Mutations of the branchpoint concensus sequence of intron 4 of lecithin: Cholesterol acyltransferase (LCAT) gene

656

2.P.62 Effect of eicosapentaenoic acid in combination with HMG-CoA reductase inhibitor on lipid metabolism

657

2.P.64 Biopharmaceutical profile of cerivastatin, a novel HMG-CoA reductase inhibitor

658

2.P.65 Stimulation of bile acid production by the ACAT inhibitor HL-004

659

2.P.66 Dose-related reduction of LDL-cholesterol in patients with primary hypercholesterolemia by atorvastatin

660

2.P.67 Prolonged inhibition of cholesterol synthesis explains the efficacy of atorvastatin

661

2.P.68 Difference in effect of simvastatin on DNA synthesis among cultured human cell types

662

2.P.69 Effect of itraconazole on serum concentrations of simvastatin and pravastatin

663

2.P.7 Age-related decline in plasma CETP and CETP mRNA expression in human adipose tissue

664

2.P.70 Effect of policosanol on smooth muscle cell proliferation in the cuffed carotid artery of the rabbit

665

2.P.71 NK-104, a potent HMGCoA-reductase inhibitor, increases intracellular degradation of apo B-100 and decreases its secretion in HepG2 cells

666

2.P.71 NK-104, a potent HMGCoA-reductase inhibitor, increases intracellular degradation of apo B-100 and decreases its secretion in HepG2 cells

667

2.P.72 Atorvastatin inhibition of NF-βB activation in vascular smooth muscle cells is mediated by protein isoprenylation blockade

668

2.P.74 Efficacy and safety of ciprofibrate and lovastatin in treatment of hyperlipidemia

669

2.P.75 Long-term effects of pravastatin in cyclosporine treated heart recipients

670

2.P.76 Fluvastatin or bezafibrate alone versus their combination

671

2.P.77 Lipid-lowering therapy in secondary prevention by Swiss primary care physicians: How far are we from the target values?

672

2.P.78 Factors associated with non-use of lipid-lowering drugs in secondary prevention of coronary heart diseases. EUROASPIRE study

673

2.P.79 Cholesteryl ester storage disease: Molecular defects and treatment with the HMGCoA-reductase inhibitor lovastatin

674

2.P.8 Expression of CETP mRNA by stromal vascular cells of human adipose tissue

675

2.P.80 Effects of cerivastatin 0.3 mg daily compared to 0.15 mg in patients with hypercholesterolemia

676

2.P.81 Limitation of heart growth in neonatal piglets by simvastatin but not pravastatin

677

2.P.82 Effect of atorvastatin vs. simvastatin in patients undergoing regular LDL-apheresis (ASLA I)

678

2.P.83 Effect of simvastatin on cholesterol homeostasis in hamsters fed a sucrose-rich lithogenic diet

679

2.P.84 Effect of simvastatin on hepatic cholesterol metabolism and biliary lipids in Australian gallstone patients

680

2.P.85 Cholesterol-independent effects of pravastatin on atherosclerotic plaque stability in primates

681

2.P.86 Effects of silymarin and silybin on lipoprotein cholesterol levels and oxidizability of low density lipoprotein in rats

682

2.P.87 Reduction of oxysterol levels up-regulates HMG-CoA reductase activity in rat liver

683

2.P.87 Reduction of oxysterol levels up-regulates HMG-CoA reductase activity in rat liver

684

2.P.88 Fluvastatin in higher dosage reduces also triglyceride rich lipoproteins

685

2.P.89 Effect of four week long treatment with fenofibrate on the level of 7-ketocholesterol in hyperlipidemic patients

686

2.P.9 Reduced plasma HDL-cholesterol levels in visceral obesity: Contribution of the CETP gene TaqIB polymorphism

687

2.P.91 Effect of Lifibrol on the metabolism of LDL-apo B and apo A-I in moderate hypercholesterolemia

688

2.P.92 Effect of MCC-134, a novel antihypertensive agent, on lipid metabolism and vascular smooth muscle cell proliferation in rats

689

2.P.93 Influence of lifibrol therapy on apoB metabolism in mixed hyperlipidemia and hypercholesterolemic patients

690

2.P.93 Influence of lifibrol therapy on apoB metabolism in mixed hyperlipidemia and hypercholesterolemic patients

691

2.P.94 Reduction of plasma cholesterol levels and inhibition of smooth muscle cell (SMC) proliferation by cerivastatin sodium, a new HMG-CoA reductase inhibitor

692

2.P.95 Effect of simvastatin and theofibrate on lipid and lipid peroxidation in type II hypercholesterolemic patients

693

2.P.96 The use of Acipimox as second line drug in severe hypertriglyceridemia and combined hyperlipidemia patients

694

2.P.97 Relation of lipoprotein Lp(a) concentration and apolipoprotein apo(a) phenotypes to the presence and severity of carotid atherosclerosis

695

2.P.98 Predictive value of lipoprotein(a) for peripheral vascular disease in a community-based cohort

696

2.P.99 A novel kringle-4 number-based recombinant apo(a) standard for human Lp(a) phenotyping

697

2.S.1 Atherothrombosis in the heart and brain: New insights into the role of plasma lipoproteins

698

2.W10.1 Regulation of apoptosis in vascular smooth muscle cells

699

2.W11.4 Comparison of risk factor levels in Framingham Cohort and Offspring participants

700

2.W11.5 Cardiovascular risk factors in coronary patients across Europe

701

2.W12.4 Percutaneous arterial gene therapy for the prevention of restenosis

702

2.W12.5 Adventitial gene transfer to rabbit carotid arteries

703

2.W13.1 Molecular genetics as tools to redefine the clinics of lipoprotein disorders: The example of lipoprotein lipase deficiency

704

2.W13.5 FDB-100: Diagnosis, laboratory and clinical findings, possibilities of treatment. Experience from homozygous and heterozygous patients

705

2.W14.2 Chronic plaque growth or acute rupture? The yin and yang of vascular connective tissue remodelling

706

2.W15.1 Different approaches to the detection and quantification of triglyceride-rich lipoprotein remnants

707

2.W15.4 Effect of triglyceride-rich lipoproteins on cholesterol transport and atherosclerosis

708

2.W15.5 Familial combined hyperlipidemia (FCH): Causes and consequences

709

2.W16.1 Hormonal replacement therapy of menopause and atherosclerosis

710

2.W16.3 Hormone replacement therapy, thrombosis, and haemostasis

711

2.W16.4 The impact of HRT on selected vascular and metabolic risk factors for atherosclerosis

712

2.W16.5 Hormonal agents used in lowering lipoprotein(a)

713

2.W17.1 Structural and functional consequences of non-enzymatic glycation of apolipoprotein A-I and its impact on the reverse cholesterol transport

714

2.W17.2 Caveolin-dependent free cholesterol efflux — major regulatory pathway in peripheral cells

715

2.W17.4 HDL and cellular cholesterol efflux

716

2.W17.5 Genetic determinants of HDL and their relationships to atherosclerosis

717

2.W18.1 Cellular metabolism of triglyceride-rich lipoproteins

718

2.W18.2 The effect of leukaemia inhibitory factor on experimental atherosclerosis

719

2.W18.3 Lipoprotein association with cells and matrix: Modulation by lipase and proteoglycans

720

2.W18.4 Arterial-wall sphingomyelinase and atherogenesis

721

2.W18.5 Lipid oxidation products as regulators of macrophage function in atherosclerosis

722

2/3 A-size rechargeable battery employing LiCoO2 thin-film cathode

723

2: External Validation of the Mortality in Emergency Department Sepsis (MEDS) Score: A Multi-Center Prospective Cohort Study

724

2: Hydrothermal ore deposits related to post-orogenic extensional magmatism and core complex formation: The Rhodope Massif of Bulgaria and Greece

725

2: Radiographs Versus CT for the Initial Diagnosis of Blunt Cervical Spine Injury: A Prospective Comparison

726

2:1 Atrioventricular Block During Atrioventricular Node Reentrant Tachycardi

727

2:1 Atrioventricular block: Order from chaos

728

2:1 Ba/Ti(IV) Heterobimetallic complex based on two calix[6]arenes

729

2-[(1E)-({[(Benzylsulfanyl)methanethioyl]amino}imino)methyl]-6-methoxyphenol: crystal structure and Hirshfeld surface analysis

730

2-[(1E)-[(Z)-2-({[(1Z)-[(E)-2-[(2-Hydroxyphenyl)methylidene]hydrazin-1-ylidene]({[(4-methylphenyl)methyl]sulfanyl})methyl]disulfanyl}({[(4-methylphenyl)methyl]sulfanyl})methylidene)hydrazin-1-ylidene]methyl]phenol: crystal structure, Hirshfeld surface analysis and computational study

731

2-[(2,4,6-Trimethylbenzene)sulfonyl]phthalazin-1(2H)-one: crystal structure, Hirshfeld surface analysis and computational study

732

2-[(4-Chlorophenyl)selanyl]-3,4-dihydro-2H-benzo[h]chromene-5,6-dione: crystal structure and Hirshfeld analysis

733

2-[(8-Dimethylaminonaphthalen-1-yl)dimethylsilyl]-N,N,4,4-tetramethyl-1,2,3,3a,4,5-hexahydro-4-sila-5,9b-ethenobenz[e]inde-9-amine. An unexpected by-product from the reaction of 1-lithio-8-dimethylaminonaphthalene with chlorodimethylvinylsilane

734

2-[(Alkylsulfonyl)oxy]-6-substituted-1H-isoindole-1,3(2H)-dione mechanism-based inhibitors of human leukocyte elastase

735

2-[(Diphenylphosphino)methyl]-6-methylpyridine (PN) coordination chemistry at triosmium clusters: Regiospecific ligand activation and DFT evaluation of the isomeric Os3(CO)10(PN) clusters

736

2-[(R-phenyl)amine]-1,4-naphthalendiones as photosystem I electron acceptors. Structure-activity relationship of m- and p-PAN compounds with QSAR analysis

737

2-[(substituted)phenyl]-5-[1-(2-phenylazacycloheptyl)methyl]-1H-pyrroles with high affinity and selectivity for the dopamine D3 receptor

738

2-[1-(2,6-Dibenzhydryl-4-chlorophenylimino)ethyl]-6-[1-(arylimino)ethyl]pyridyliron(II) dichlorides: Synthesis, characterization and ethylene polymerization behavior

739

2-[1-(2,6-dibenzhydryl-4-chlorophenylimino)ethyl]-6-[1-aryliminoethyl]pyridyl cobalt dichlorides: Synthesis, characterization and ethylene polymerization behavior

740

2-[1-(2,6-Dibenzhydryl-4-methylphenylimino)ethyl]-6-[1-(arylimino)ethyl]pyridylnickel(II) halides: Synthesis, characterization and ethylene oligomerization behavior

741

2-[18F]-Fluoro-2-deoxy-d-glucose positron emission tomography as guidance for primary treatment in patients with advanced-stage resectable squamous cell carcinoma of the larynx and hypopharynx

742

2-[18f]-Fluoro–2-deoxy-d-glucose positron emission tomography in the evaluation of breast lesions and axillary involvement: a comparison with mammography and histopathological diagnosis

743

2-[18F]-fluoroisonicotinic acid hydrazide: biological evaluation in an acute infection model

744

2-[2-(4-Methoxyphenyltelluro)ethyl]thiophene (L1) bis[2-(2-thienyl)ethyl] telluride (L2) and their metal complexes; crystal structure of trans-dichlorobis{2-(2-(4-methoxyphenyltelluro)ethyl)thiophene-Te}palladium(II) and {bis[2-(2-thienyl)ethyl] telluride

745

2-[4-(Dimethylamino)phenyl]-3-hydroxy-4H-chromene-4-one: A H-bond-sensitive fluorescent probe for investigating binary mixtures of organic solvents Original Research Article

746

2-[4-(o-methoxyphenyl)piperazin-1-ylmethyl]-1,3-dioxoperhydroimidazo[1,5-a]pyridine as a new selective 5-HT1A receptor ligand

747

2-[Carbamothioyl(2-hydroxyethyl)amino]ethyl benzoate: crystal structure, Hirshfeld surface analysis and computational study

748

2-[N1-2-Pyrimidyl-aminobenzenesulfonamido] ethyl 4-bis(2-chloroethyl) aminophenyl butyrate: A potent antitumor agent

749

2-{(1E)-[(E)-2-(2,6-Dichlorobenzylidene)hydrazin-1-ylidene]methyl}phenol: crystal structure, Hirshfeld surface analysis and computational study

750

2-{[1-(3,4-Dihydroxyphenyl)methylidene]amino}benzoic acid immobilized Amberlite XAD-16 as metal extractant

751

2-{2-[3-(Pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl}pyridine: a highly potent, orally active, metabotropic glutamate subtype 5 (mGlu5) receptor antagonist

752

2′,2′-Ligation demonstrates the thermal dependence of DNA-directed positional control

753

2′,3′,4′,5′-Tetraacetyl-N(3)-carboxymethylriboflavin derivatives: synthesis and fluorescence studies

754

2′,3′-Didehydro-2′,3′-dideoxynucleosides are degraded to furfuryl alcohol under acidic conditions

755

2′,5′-Oligoadenylate-peptide nucleic acids (2–5A-PNAs) activate RNase L Original Research Article

756

2′-Amino-2′-deoxy-N6-(1-naphthylmethyl)adenosine as Novel Scaffold for a Polymer-Assisted Amidation Protocol

757

2′-Behenoyl-paclitaxel conjugate containing lipid nanoparticles for the treatment of metastatic breast cancer

758

2′-Carboxybenzyl glycosides: glycosyl donors for C-glycosylation and conversion into other glycosyl donors

759

2′-C-Methyluridine phosphoramidite: a new building block for the preparation of RNA analogues carrying the 2′-hydroxyl group

760

2′-Deoxy-2′(S)-ethinyl oligonucleotides: A modification which selectively stabilizes oligoadenylate pairing to DNA complements

761

2′-deoxy-8-(propyn-1-yl)adenosine-containing oligonucleotides: effects on stability of duplex and quadruplex structures

762

2′-Deoxyadenylyl-(3′→5′)-isodideoxyadenosine, a unique dinucleotide: Synthesis, enzymology, and conformational studies

763

2′-deoxycytidine in free nucleosides and double-stranded dna as the major target of lipid peroxidation products

764

2′-deoxyguanosine oxidation is associated with decrease in the DNA-binding activity of the transcription factor Sp1 in liver and kidney from diabetic and insulin-resistant rats

765

2′-Deoxy-N4-[2-(4-nitrophenyl)ethoxycarbonyl]-5-azacytidine: A novel inhibitor of DNA methyltransferase that requires activation by human carboxylesterase 1

766

2′-Fluoro Substituents Can Mimic Native 2′-Hydroxyls within Structured RNA

767

2′-Fluoro-3-deazaaristeromycin

768

2′-Hydroxyflavylium: introducing flavanones into the flavylium network of chemical reactions

769

2′-Lipid-modified oligonucleotides via a ‘Staudinger–Vilarrasa’ reaction

770

2′-Methyl and 1′-xylosyl derivatives of 2′-hydroxyflexixanthin are major carotenoids of Hymenobacter species

771

2′-Methyl taxanes: synthesis and NMR configurational assignment

772

2′-Nitroflavone induces cell cycle arrest and apoptosis in HeLa human cervical carcinoma cells

773

2′-O,4′-C-ethylene-bridged nucleic acids (ENA): highly nuclease-resistant and thermodynamically stable oligonucleotides for antisense drug

774

2′-O,4′-C-methylene bridged nucleic acid (2′,4′-BNA): synthesis and triplex-forming properties Original Research Article

775

2′-O-{[2,2-dimethyl-2-(2-nitrophenyl) acetyl] oxy} methyl protecting group for RNA synthesis

776

2′-O-Carbamate-containing oligonucleotides: synthesis and properties

777

2″-O-Glucosylvitexin, a chemotaxonomic marker for the genus Cryptocoryne (Araceae)

778

2″-Substituted 5-phenylterbenzimidazoles as topoisomerase I poisons Original Research Article

779

2+1 dimensional charged black hole with (anti-)self dual Maxwell fields

780

2+1 resonance-enhanced multiphoton ionisation spectroscopy of the high ν2 levels of the B̃1E″ Rydberg state of NH3(ND3)

781

2+1+1 two-color REMPI study of the E1Π(ν=1)←D1Δ(ν=10)←X1Σ+(ν=0) transition in CO: influence of the accidental predissociation in the CO E1Π(ν=1) state at j=9 and 10

782

2+2 may (or may not) yield 4

783

2× oversampling 2.5 Gbps clock and data recovery with phase picking method

784

2×2 superlattices

785

2×2 systems of conservation laws with L∞ data

786

2×CO2 Eastern Asia regional responses in the RSM/CCM3 modeling system

787

2·5 year remission of AIDS-associated progressive multifocal leukoencephalopathy with combined antiretroviral therapy

788

20 000 brains removed and retained without relativesʹ consent

789

20 Isometric strength of the small tears of the rotator cuff

790

20 K Energy storage unit Original Research Article

791

20 million contract

792

20 Mini vs. open repair of isolated supraspinatus tendon tears

793

20 most-cited countries in clinical medicine ranked by population size

794

20 Myr of eccentricity paced lacustrine cycles in the Cenozoic Ebro Basin

795

20 Pravastatin protects against development of chronic rejection in rat cardiac allografts and upregulates immunosuppressive TGF-B2

796

20 S proteasomes are imported as precursor complexes into the nucleus of yeast

797

20 Segment based interpolation revisited

798

20 thickened, fragile nails

799

20 years of active deformation on volcano caldera: Joint analysis of InSAR and AInSAR techniques

800

20 Years of Cardiac Resynchronization Therapy

801

20 years of experience in idiopathic central diabetes insipidus

802

20 years of mass balances on the Piloto glacier, Las Cuevas river basin, Mendoza, Argentina

803

20 years of patch testing with (meth)acrylates

804

20 years of scripted space

805

20% loss of unimproved farmland in 22 years in the Engadin, Swiss Alps

806

20% of sufferers could outgrow peanut allergy

807

20 My of nitrogen fixation during deposition of mid-Cretaceous black shales on the Demerara Rise, equatorial Atlantic Ocean

808

20(S)-Protopanaxatriol, one of ginsenoside metabolites, inhibits inducible nitric oxide synthase and cyclooxygenase-2 expressions through inactivation of nuclear factor-κB in RAW 264.7 macrophages stimulated with lipopolysaccharide

809

20. Clinical and radiological predictors of complete excision in breast conserving treatment

810

20. Declining motor unit number estimates in a murine model of kennedy’s disease

811

20. Evaluation of oestrogen and progesterone receptors in breast cancer by comparing computer-assisted image analysis of immunocytochemical assay with enzyme immunoassay

812

20. Heart failure transition clinics: Can they reduce heart failure readmissions?

813

20. Heart failure… at home – sweet home

814

20. Multimodal intraoperative monitoring during spine surgery

815

20. rCBF measured by NIRS varies with the deep brain stimulation for STN

816

20/20 Foresight Crafting Strategy in an Uncertain World,: by Hugh Courtney, Harvard Business School Press, Boston, Massachusetts, 2001. ISBN 1-57851-266-2.

817

20/sup st/ century engineer-entrepreneur

818

20: A Comparison of Endotracheal Intubation Success Rates Between Providers of a Metropolitan Air Medical Transport Service

819

20: CT Coronary Angiography During Initial Visit Decreases Rate of Return Visits Relative To Standard Care

820

200 junior doctors sacked in Zambia

821

200 MeV Ag+15 ion irradiation created columnar defects and enhanced critical current density of La-2125 type superconducting thin films

822

200 MeV Ag15+ ion induced surface modification and transport behaviour in manganite based thin film devices

823

200 Years of British Hydrogeology, Mather J.D. (Ed.). Geological Society, London (2004), 394

824

200 years of practical electroanalytical chemistry: past, present and future directions illustrated by reference to the on-line, on-stream and off-line determination of trace metals in zinc plant electrolyte by voltammetric and potentiometric techniques O

825

200 000 yr diatom records from Atlantic upwelling sites reveal maximum productivity during LGM and a shift in phytoplankton community structure at 185 000 yr

826

2000 ACC/AHA guidelines for the management of patients with unstable angina and non–ST-segment elevation myocardial infarction: A practical summary for emergency physicians

827

2000 ACM Conference on Intelligent User Interfaces

828

2000 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System

829

2000 John Cedric Griffiths teaching award of the international association for mathematical geology

830

2000 Shanghai Magnolia Award

831

2000 to 2015: How Far Have We Progressed in Achieving the Health Related Millennium Development Goals?

832

2000 years of sustainable use of watersheds and coral reefs in Pacific Islands: A review for Palau

833

2000 ans de colmatage du port antique de Fréjus (Forum Julii), France : une double métamorphose littorale

834

2000 years of frequent turbidite activity in the Capbreton Canyon (Bay of Biscay)

835

200000 yr diatom records from Atlantic upwelling sites reveal maximum productivity during LGM and a shift in phytoplankton community structure at 185000 yr

836

2000–2003 real estate bubble in the UK but not in the USA

837

2000-Ma sulphide concretions from the `Productiveʹ Formation of the Pechenga Greenstone Belt, NW Russia: genetic history based on morphological and isotopic evidence

838

2000-year environmental history of a karstic lake in the Mediterranean Pre-Pyrenees: the Estanya lakes (Spain)

839

2001 – A Controversy

840

2001 Ambassador Award: Mid-Atlantic Chapter Society of Toxicology

841

2001 assessment of nutritional influences on risk for cataract

842

2001 Bhuj, India, Earthquake Engineering Seismoscope Recordings and Eastern North America Ground-Motion Attenuation Relations

843

2001 consensus guidelines for the management of women with cervical intraepithelial neoplasia

844

2001 Consensus guidelines for the management of women with cervical intraepithelial neoplasia

845

2001 Cumulative article and author index volume 44, number 6

846

2001 Felix Chayes prize for excellence in research in mathematical petrology of the international association for mathematical geology

847

2001 flank eruption of the alkali- and volatile-rich primitive basalt responsible for Mount Etnaʹs evolution in the last three decades

848

2001 ISPMB discounts for Plant Molecular Biology

849

2001 Kumho Science International Award in Plant Molecular Biology and Biotechnology Award Presentation ceremony

850

2001 LCATS research award

851

2001 meeting Southern Thoracic Surgical Association

852

2001 transcatheter cardiovascular therapeutics

853

2001 transcatheter cardiovascular therapeutics

854

2001 transcatheter cardiovascular therapeutics

855

2001 UTS Society for Utopian studies conf

856

2001: A Veterinary Odyssey – Here and Now

857

2001—the year for health-research ethics to take centre stage?

858

2002 AA29: Earthʹs recurrent quasi-satellite?

859

2002 annual report of the American association of poison control centers toxic exposure surveillance system

860

2002 Elections in Pakistan: A Reappraisal

861

2002 Henry H. Storch Award

862

2002 Kuiper prize lecture: Dust Astronomy

863

2002 Kumho Science International Award in Plant Molecular Biology and Biotechnology

864

2002 Leonid storm fluxes and related orbital elements

865

2002 Reviewers List

866

2002 Rumelhart prizewinner

867

2002 St. Christopher lecture

868

2002 state of the science: Celebration of sharing

869

2002 summer fires in Lithuania: Impact on the Vilnius city air quality and the inhabitants health

870

2002 update to the ACC/AHA guidelines for the management of patients with unstable angina and non–ST-segment elevation myocardial infarction: Implications for emergency department practice

871

2002 Winter Conference on Plasma Spectrochemistry: Scottsdale Arizona 6–12 January 2002

872

2002: the year of the ‘diversity – ecosystem function’ debate

873

2002-2008 Yılları Arasında Erzurum Bölgesinde Birinci ve İkinci Basamak Sağlık Hizmetlerinin Değerlendirilmesi

874

2003 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System ,

875

2003 Author index

876

2003 European Winter Conference: 2003 European Conference on Plasma Spectrochemistry January 12–17, 2003

877

2003 International Ash Utilization Symposium

878

2003 Kumbo Science International Award in Plant Molecular Biology and Biotechnology: Awardee is Xing-Wang Deng

879

2003 Kumho Science International Award in Plant Molecular Biology and Biotechnology

880

2003 LCATS Research Award: Robert P. Holley

881

2003 Meeting Southern Thoracic Surgical Association

882

2003 Performance Evaluation reviewers

883

884

2003 Space Cryogenics Workshop, 18–19 September 2003, Girdwood, Alaska

885

2003 Subject index

886

2003 transcatheter cardiovascular therapeutics

887

2003: A centennial of spinthariscope and scintillation counting

888

2004 American College of Cardiology/American Heart Association Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: Implications for Emergency Department Practice

889

2004 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System

890

2004 AONE Award winner profiles

891

2004 Author index

892

2004 Eurographics Symposium on Parallel Graphics and Visualization

893

2004 Henry H. Storch Award

894

2004 Indian Ocean tsunami inflow and outflow at Phuket, Thailand

895

2004 ISPMB membership renewals

896

2004 John Cedric Griffiths Teaching Award to Jack Schuenemeyer

897

2004 Meeting Southern Thoracic Surgical Association

898

2004 Optical Society of Americas Topical Meeting on Optical Interference Coatings: manufacturing problem

899

2004 pediatric emergency medicine recertification examination

900

2004 Performance Evaluation reviewers

901

2004 Presidential campaign messages: A functional analysis of press releases from President Bush and Senator Kerry

902

2004 Psychoneuroimmunology Research Meeting Abstracts 101–150

903

2004 Psychoneuroimmunology Research Meeting Abstracts 1–50

904

2004 Psychoneuroimmunology Research Meeting Abstracts 151–205

905

2004 Psychoneuroimmunology Research Meeting Abstracts 51–100

906

2004 sports medicine subspecialty certification and recertification examination

907

2004 State of the Science and Science to Practice

908

2004 Subject index

909

2004 Survey of United States architects on the subject of switchable glazings

910

2004–2005 Analytical Developments in Secondary Ion Mass Spectrometry

911

2005 Author index

912

2005 Best Paper Award Recipients: A Message from the Editor-in-Chief

913

2005 Call for Papers

914

2005 IEEE East-West Design and Test Workshop

915

2005 IEEE/WIC/ACM International Joint Conference on Web Intelligence and Intelligent Agent Technology (WI-IAT’05)

916

2005 Kumho award recipient

917

2005 List of reviewers for Automatica

918

2005 Meeting Southern Thoracic Surgical Association

919

2005 Photometric observations and multiple frequencies of the δ Scuti variable CC And

920

921

2005 State of the Future (Millennium Project), American Council for the United Nations University (2005) plus CD-Rom.

922

2005 Subject index

923

2005 was a good year for Japanʹs carbon black industry

924

2006 ACS Award Issue “For Creative Work in Fluorine Chemistry” Kenji Uneyama

925

2006 Acta Materialia, Inc. Gold Medal

926

2006 Acta Materialia, Inc. J. Herbert Hollomon Award

927

2006 clinical immunology school on systemic autoimmune diseases

928

2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests

929

2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ

930

2006 Eurographics Symposium on Parallel Graphics and Visualization

931

2006 Fragmentation of Comet 73P/Schwassmann-Wachmann 3B observed with Subaru/Suprime-Cam

932

2006 Gondwana Research Best Paper Award

933

2006 Henry H. Storch Award in Fuel Chemistry goes to Colin Snape

934

2006 International symposium on biomedical engineering, Taiwan (2006-ISOBME)

935

2006 John Cedric Griffiths Teaching Award to Paul Switzer

936

2006 Latin American Test Workshop

937

2006 list of reviewers for Automatica

938

2006 Meeting Southern Thoracic Surgical Association

939

2006 Performance Evaluation reviewers

940

2006 Research Award

941

942

2006 Reviewers List (PDF)

943

2006 Sarawak State Elections: Issues and Electoral Results

944

2007 Acta Materialia, Inc. Gold Medal

945

2007 Annual meeting of the Society of Urologic Oncology and the Society of Basic Urologic Research: Introduction

946

2007 Award of Merit Acceptance Speech

947

2007 Chronic Angina Focused Update of the ACC/AHA 2002 Guidelines for the Management of Patients With Chronic Stable Angina: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to Devel

948

2007 Editorsʹ Collection

949

2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction Review Article

950

2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention Review Article

951

2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings

952

2007 Henry H. Storch Award in Fuel Chemistry goes to Ronald J. Pugmire

953

2007 Index IEEE Transactions On Nanotechnology Vol. 6

954

2007 list of reviewers for Automatica

955

2007 Mutual events within the binary system of (22) Kalliope

956

957

2007 SEI and ASCE Structural Awards

958

2007 Space Cryogenics Workshop

959

2007 will be a highlight in the life of the International Institute of Refrigeration

960

2007 Counselling Psychology in India: At the Confluence of Two Traditions

961

2007-2008 Discussions on Predictability of The Global Financial Crisis

962

2008 ACS Award Issue “For Creative Work in Fluorine Chemistry”, Dennis P. Curran

963

2008 Acta Materialia, Inc. J. Herbert Hollomon Award

964

2008 Australian Organic Geochemistry Conference. A national conference held in association with the International Humic Substances Society and the Natural Organic Matter Interest Group

965

2008 Benjamin Franklin medal in life science is Presented to Victor Ambros, Ph.D. (University of Massachusetts Medical School, Worcester, Massachusetts), Gary Ruvkun, Ph.D. (Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts) an

966

2008 Bower Award and Prize for Achievement in Science

967

2008 Economics Crisis in Malaysia: Implications on the Economy,Society and Safety Nets

968

2008 Editorsʹ Collection

969

2008 Fuel Chemistry Division Storch Award

970

2008 General Elections in Malaysia: Democracy at Work

971

2008 General Elections in Malaysia: Democracy at Work

972

2008 Gondwana Research Best Paper Award

973

974

2008 John Cedric Griffiths Teaching Award to Vera Pawlowsky

975

2008 list of reviewers for Automatica

976

977

2008 Whitmore Lecture: Radical prostatectomy—where we were and where we are going

978

2009 ACCF/AHA Focused Update on Perioperative Beta Blockade

979

2009 Acta Materialia, Inc. Gold Medal Award

980

2009 Acta Materialia, Inc. Materials & Society Award (Formerly the J. Herbert Holloman Award)

981

2009 CALPHAD Awards

982

2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With th

983

2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guid

984

2009 IAGR Annual Convention and 6th International Symposium on Gondwana to Asia

985

986

2009 list of reviewers for Automatica

987

2009 Quality survey of retail biodiesel blends in Michigan

988

2009 Space Cryogenics Workshop

989

2009 Summer Forum for Present and Future of HIFU Treatment on Gynecological Diseases held in Chongqing, P.R. China (18–24 July 2009)

990

2009 Summer Forum for Present and Future of HIFU Treatment on Gynecological Diseases held in Chongqing, P.R. China (18–24 July 2009)

991

200-MeV bremsstrahlung tagged photon beams at Sendai

992

200-MeV bremsstrahlung tagged photon beams at Sendai

993

200-mW-Average Power Ultraviolet Generation at 0.193 (mu)m in K2Al2B2O7

994

2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With

995

2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease: Executive Summary

996

2010 Acta Biomaterialia Gold Medal

997

2010 Acta Materialia Materials and Society Award

998

2010 Acta Materialia, Inc. Gold Medal Award

999

2010 ASIS&T James M. Cretsos Leadership Award

1000

2010 IAGR Annual Convention and 7th International Symposium on Gondwana to Asia

بازگشت